109 results on '"Szucs, Gabriella"'
Search Results
2. Should we use nintedanib as early therapy in patients with SSc-ILD?
- Author
-
Zanatta, Elisabetta, Moccaldi, Beatrice, Szucs, Gabriella, and Spagnolo, Paolo
- Published
- 2024
- Full Text
- View/download PDF
3. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
- Author
-
Au Peh, Chen, Chakera, Aron, Cooper, Bruce, Kurtkoti, Jagadeesh, Langguth, Daman, Levidiotis, Vicki, Luxton, Grant, Mount, Peter, Mudge, David, Noble, Euan, Phoon, Richard, Ranganathan, Dwarakanathan, Ritchie, Angus, Ryan, Jessica, Suranyi, Michael, Rosenkranz, Alexander, Lhotta, Karl, Kronbichler, Andreas, Demoulin, Nathalie, Bovy, Christophe, Hellemans, Rachel, Hougardy, Jean-Michel, Sprangers, Ben, Wissing, Karl Martin, Pagnoux, Christian, Barbour, Sean, Brachemi, Soumeya, Cournoyer, Serge, Girard, Louis-Philippe, Laurin, Louis-Philippe, Liang, Patrick, Philibert, David, Walsh, Michael, Tesar, Vladimir, Becvar, Radim, Horak, Pavel, Rychlik, Ivan, Szpirt, Wladimir, Dieperink, Hans, Gregersen, Jon Waarst, Ivarsen, Per, Krarup, Elizabeth, Lyngsoe, Cecilie, Rigothier, Claire, Augusto, Jean-Francois, Belot, Alexandre, Chauveau, Dominique, Cornec, Divi, Jourde-Chiche, Noemie, Ficheux, Maxence, Karras, Alexandre, Klein, Alexandre, Maurier, Francois, Mesbah, Rafik, Moranne, Olivier, Neel, Antoine, Quemeneur, Thomas, Saadoun, David, Terrier, Benjamin, Zaoui, Philippe, Schaier, Matthias, Benck, Urs Tobias, Bergner, Raoul, Busch, Martin, Floege, Juergen, Grundmann, Franziska, Haller, Hermann, Haubitz, Marion, Hellmich, Bernhard, Henes, Joerg Christoph, Hohenstein, Bernd, Hugo, Christian, Iking-Konert, Christof, Arndt, Fabian, Kubacki, T, Kotter, Ina, Lamprecht, Peter, Lindner, Tom, Halbritter, Jan, Mehling, Heidrun, Schönermarck, Ulf, Venhoff, Nils, Vielhauer, Volker, Witzke, Oliver, Szombati, Istvan, Szucs, Gabriella, Garibotto, Giacomo, Alberici, Federico, Brunetta, Enrico, Dagna, Lorenzo, De Vita, Salvatore, Emmi, Giacomo, Gabrielli, Armando, Manenti, Lucio, Pieruzzi, Federico, Roccatello, Dario, Salvarani, Carlo, Harigai, Masayoshi, Dobashi, Hiroaki, Atsumi, Tatsuya, Fujimoto, Shoichi, Hagino, Noboru, Ihata, Atsushi, Kaname, Shinya, Kaneko, Yuko, Katagiri, Akira, Katayama, Masao, Kirino, Yohei, Kitagawa, Kiyoki, Komatsuda, Atsushi, Kono, Hajime, Kurasawa, Takahiko, Matsumura, Ryutaro, Mimura, Toshihide, Morinobu, Akio, Murakawa, Yohko, Naniwa, Taio, Nanki, Toshihiro, Ogawa, Noriyoshi, Oshima, Hisaji, Sada, Kenei, Sugiyama, Eiji, Takeuchi, Tohru, Taki, Hirofumi, Tamura, Naoto, Tsukamoto, Tatsuo, Yamagata, Kunihiro, Yamamura, Masahiro, van Daele, Paulus Leon Arthur, Rutgers, Abraham, Teng, Y.K. Onno, Walker, Robert, Chua, Ignatius, Collins, Michael, Rabindranath, Kannaiyan, de Zoysa, Janak, Svensson, My Hanna Sofia, Grevbo, Bard-Waldum, Kalstad, Synove, Little, Mark, Clarkson, Michael, Molloy, Eamonn, Agraz Pamplona, Irene, Anton, Jordi, Barrio Lucia, Vicente, Ciggaran, Secundino, Cinta Cid, Maria, Diaz Encarnacion, Montserrat, Fulladosa Oliveras, Xavier, Jose Soler, Maria, Marco Rusinol, Helena, Praga, Manuel, Quintana Porras, Luis, Segarra, Alfons, Bruchfeld, Annette, Segelmark, Marten, Soveri, Inga, Thomaidi, Eleni, Westman, Kerstin, Neumann, Thomas, Burnier, Michel, Daikeler, Thomas, Dudler, Jean, Hauser, Thomas, Seeger, Harald, Vogt, Bruno, Burton, James, Al Jayyousi, Reem, Amin, Tania, Andrews, Jacqueline, Baines, Laura Anne, Brogan, Paul, Dasgupta, Bhaskar, Doulton, Timothy William Ronald, Flossmann, Oliver, Griffin, Sian V., Harper, Janice Marian, Harper, Lorraine, Kidder, Dana, Klocke, Rainer, Lanyon, Peter Charles, Luqmani, Raashid, McLaren, John Stuart, Makanjuola, David Osagie, McCann, Liza, Nandagudi, Anupama C., Selvan, Shilpa, O'Riordan, Edmond, Patel, Mumtaz, Patel, Rajan Kantilal, Pusey, Charles Dickson, Rajakariar, Ravindra, Robson, Joanna C., Robson, Michael, Salama, Alan David, Smyth, Lucy, Sznajd, Jan, Taylor, Joanne, Sreih, Antonie G., Belilos, Elise, Bomback, Andrew S., Carlin, Jeffrey, Chang Chen Lin, Yih, Derebail, Vimal K., Dragoi, Serban, Dua, Anisha, Forbess, Lindsy, Geetha, Duvuru, Gipson, Patrick, Gohh, Reginald, Greenwood, Gregory Todd, Hugenberg, Steven T., Jimenez, Richard A.H., Kaskas, Marwan Omar, Kermani, Tanaz, Kivitz, Alan J., Koening, Curry, Langford, Carol A., Marder, Galina, Mohamed, Amr Ahmed El-Huesseini, Monach, Paul, Neyra, Nilda Roxana, Niemer, Gregory W., Niles, John, Obi, Reginald, Owens, Charles, Parks, Deborah L., Podoll, Amber S., Rovin, Brad, Sam, R, Shergy, William Julius, Silva, Arnold Lawrence, Specks, Ulrich, Spiera, Robert, Springer, Jason M., Striebich, Christopher Charles, Swarup, Areena, Thakar, Surabhi, Tiliakos, Athan N., Tsai, Yong, Waguespack, Dia R., Chester Wasko, Mary, Strand, Vibeke, Jayne, David R W, Horomanski, Audra, Yue, Huibin, Bekker, Pirow, and Merkel, Peter A
- Published
- 2023
- Full Text
- View/download PDF
4. Novel aspects of muscle involvement in immune-mediated inflammatory arthropathies and connective tissue diseases
- Author
-
Mogyoróssy, Sándor, Nagy-Vincze, Melinda, Griger, Zoltán, Dankó, Katalin, Szabó, Nóra Anna, Szekanecz, Zoltán, Szűcs, Gabriella, Szántó, Antónia, and Bodoki, Levente
- Published
- 2023
- Full Text
- View/download PDF
5. Anti-neutrophil cytoplasmic antibody testing by indirect immunofluorescence: Computer-aided versus conventional microscopic evaluation of routine diagnostic samples from patients with vasculitis or other inflammatory diseases
- Author
-
Nagy, Gábor, Csípő, István, Tarr, Tünde, Szűcs, Gabriella, Szántó, Antónia, Bubán, Tamás, Sipeki, Nóra, Szekanecz, Zoltán, Papp, Mária, Kappelmayer, János, and Antal-Szalmás, Péter
- Published
- 2020
- Full Text
- View/download PDF
6. Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases
- Author
-
Szekanecz, Zoltán, Gomez, Izabella, Soós, Boglárka, Bodoki, Levente, Szamosi, Szilvia, András, Csilla, Juhász, Balázs, Váróczy, László, Antal-Szalmás, Péter, Szodoray, Péter, Bittner, Nóra, Árkosy, Péter, Illés, Árpád, Szűcs, Gabriella, Dankó, Katalin, Bender, Tamás, Tamási, László, and Szekanecz, Éva
- Published
- 2020
- Full Text
- View/download PDF
7. An in vivo confocal microscopy study of corneal changes in patients with systemic sclerosis
- Author
-
Szalai, Eszter, Szucs, Gabriella, Szamosi, Szilvia, Aszalos, Zsuzsa, Afra, Ildiko, and Kemeny-Beke, Adam
- Published
- 2021
- Full Text
- View/download PDF
8. Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis
- Author
-
Balogh, Emese, Pusztai, Anita, Hamar, Attila, Végh, Edit, Szamosi, Szilvia, Kerekes, György, McCormick, Jennifer, Biniecka, Monika, Szántó, Sándor, Szűcs, Gabriella, Nagy, Zoltán, Fearon, Ursula, Veale, Douglas J., and Szekanecz, Zoltán
- Published
- 2019
- Full Text
- View/download PDF
9. Should we use nintedanib as early therapy in patients with SSc-ILD?
- Author
-
Zanatta, Elisabetta, primary, Moccaldi, Beatrice, additional, Szucs, Gabriella, additional, and Spagnolo, Paolo, additional
- Published
- 2023
- Full Text
- View/download PDF
10. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
- Author
-
Strand, Vibeke, primary, Jayne, David R W, additional, Horomanski, Audra, additional, Yue, Huibin, additional, Bekker, Pirow, additional, Merkel, Peter A, additional, Au Peh, Chen, additional, Chakera, Aron, additional, Cooper, Bruce, additional, Kurtkoti, Jagadeesh, additional, Langguth, Daman, additional, Levidiotis, Vicki, additional, Luxton, Grant, additional, Mount, Peter, additional, Mudge, David, additional, Noble, Euan, additional, Phoon, Richard, additional, Ranganathan, Dwarakanathan, additional, Ritchie, Angus, additional, Ryan, Jessica, additional, Suranyi, Michael, additional, Rosenkranz, Alexander, additional, Lhotta, Karl, additional, Kronbichler, Andreas, additional, Demoulin, Nathalie, additional, Bovy, Christophe, additional, Hellemans, Rachel, additional, Hougardy, Jean-Michel, additional, Sprangers, Ben, additional, Wissing, Karl Martin, additional, Pagnoux, Christian, additional, Barbour, Sean, additional, Brachemi, Soumeya, additional, Cournoyer, Serge, additional, Girard, Louis-Philippe, additional, Laurin, Louis-Philippe, additional, Liang, Patrick, additional, Philibert, David, additional, Walsh, Michael, additional, Tesar, Vladimir, additional, Becvar, Radim, additional, Horak, Pavel, additional, Rychlik, Ivan, additional, Szpirt, Wladimir, additional, Dieperink, Hans, additional, Gregersen, Jon Waarst, additional, Ivarsen, Per, additional, Krarup, Elizabeth, additional, Lyngsoe, Cecilie, additional, Rigothier, Claire, additional, Augusto, Jean-Francois, additional, Belot, Alexandre, additional, Chauveau, Dominique, additional, Cornec, Divi, additional, Jourde-Chiche, Noemie, additional, Ficheux, Maxence, additional, Karras, Alexandre, additional, Klein, Alexandre, additional, Maurier, Francois, additional, Mesbah, Rafik, additional, Moranne, Olivier, additional, Neel, Antoine, additional, Quemeneur, Thomas, additional, Saadoun, David, additional, Terrier, Benjamin, additional, Zaoui, Philippe, additional, Schaier, Matthias, additional, Benck, Urs Tobias, additional, Bergner, Raoul, additional, Busch, Martin, additional, Floege, Juergen, additional, Grundmann, Franziska, additional, Haller, Hermann, additional, Haubitz, Marion, additional, Hellmich, Bernhard, additional, Henes, Joerg Christoph, additional, Hohenstein, Bernd, additional, Hugo, Christian, additional, Iking-Konert, Christof, additional, Arndt, Fabian, additional, Kubacki, T, additional, Kotter, Ina, additional, Lamprecht, Peter, additional, Lindner, Tom, additional, Halbritter, Jan, additional, Mehling, Heidrun, additional, Schönermarck, Ulf, additional, Venhoff, Nils, additional, Vielhauer, Volker, additional, Witzke, Oliver, additional, Szombati, Istvan, additional, Szucs, Gabriella, additional, Garibotto, Giacomo, additional, Alberici, Federico, additional, Brunetta, Enrico, additional, Dagna, Lorenzo, additional, De Vita, Salvatore, additional, Emmi, Giacomo, additional, Gabrielli, Armando, additional, Manenti, Lucio, additional, Pieruzzi, Federico, additional, Roccatello, Dario, additional, Salvarani, Carlo, additional, Harigai, Masayoshi, additional, Dobashi, Hiroaki, additional, Atsumi, Tatsuya, additional, Fujimoto, Shoichi, additional, Hagino, Noboru, additional, Ihata, Atsushi, additional, Kaname, Shinya, additional, Kaneko, Yuko, additional, Katagiri, Akira, additional, Katayama, Masao, additional, Kirino, Yohei, additional, Kitagawa, Kiyoki, additional, Komatsuda, Atsushi, additional, Kono, Hajime, additional, Kurasawa, Takahiko, additional, Matsumura, Ryutaro, additional, Mimura, Toshihide, additional, Morinobu, Akio, additional, Murakawa, Yohko, additional, Naniwa, Taio, additional, Nanki, Toshihiro, additional, Ogawa, Noriyoshi, additional, Oshima, Hisaji, additional, Sada, Kenei, additional, Sugiyama, Eiji, additional, Takeuchi, Tohru, additional, Taki, Hirofumi, additional, Tamura, Naoto, additional, Tsukamoto, Tatsuo, additional, Yamagata, Kunihiro, additional, Yamamura, Masahiro, additional, van Daele, Paulus Leon Arthur, additional, Rutgers, Abraham, additional, Teng, Y.K. Onno, additional, Walker, Robert, additional, Chua, Ignatius, additional, Collins, Michael, additional, Rabindranath, Kannaiyan, additional, de Zoysa, Janak, additional, Svensson, My Hanna Sofia, additional, Grevbo, Bard-Waldum, additional, Kalstad, Synove, additional, Little, Mark, additional, Clarkson, Michael, additional, Molloy, Eamonn, additional, Agraz Pamplona, Irene, additional, Anton, Jordi, additional, Barrio Lucia, Vicente, additional, Ciggaran, Secundino, additional, Cinta Cid, Maria, additional, Diaz Encarnacion, Montserrat, additional, Fulladosa Oliveras, Xavier, additional, Jose Soler, Maria, additional, Marco Rusinol, Helena, additional, Praga, Manuel, additional, Quintana Porras, Luis, additional, Segarra, Alfons, additional, Bruchfeld, Annette, additional, Segelmark, Marten, additional, Soveri, Inga, additional, Thomaidi, Eleni, additional, Westman, Kerstin, additional, Neumann, Thomas, additional, Burnier, Michel, additional, Daikeler, Thomas, additional, Dudler, Jean, additional, Hauser, Thomas, additional, Seeger, Harald, additional, Vogt, Bruno, additional, Burton, James, additional, Al Jayyousi, Reem, additional, Amin, Tania, additional, Andrews, Jacqueline, additional, Baines, Laura Anne, additional, Brogan, Paul, additional, Dasgupta, Bhaskar, additional, Doulton, Timothy William Ronald, additional, Flossmann, Oliver, additional, Griffin, Sian V., additional, Harper, Janice Marian, additional, Harper, Lorraine, additional, Kidder, Dana, additional, Klocke, Rainer, additional, Lanyon, Peter Charles, additional, Luqmani, Raashid, additional, McLaren, John Stuart, additional, Makanjuola, David Osagie, additional, McCann, Liza, additional, Nandagudi, Anupama C., additional, Selvan, Shilpa, additional, O'Riordan, Edmond, additional, Patel, Mumtaz, additional, Patel, Rajan Kantilal, additional, Pusey, Charles Dickson, additional, Rajakariar, Ravindra, additional, Robson, Joanna C., additional, Robson, Michael, additional, Salama, Alan David, additional, Smyth, Lucy, additional, Sznajd, Jan, additional, Taylor, Joanne, additional, Sreih, Antonie G., additional, Belilos, Elise, additional, Bomback, Andrew S., additional, Carlin, Jeffrey, additional, Chang Chen Lin, Yih, additional, Derebail, Vimal K., additional, Dragoi, Serban, additional, Dua, Anisha, additional, Forbess, Lindsy, additional, Geetha, Duvuru, additional, Gipson, Patrick, additional, Gohh, Reginald, additional, Greenwood, Gregory Todd, additional, Hugenberg, Steven T., additional, Jimenez, Richard A.H., additional, Kaskas, Marwan Omar, additional, Kermani, Tanaz, additional, Kivitz, Alan J., additional, Koening, Curry, additional, Langford, Carol A., additional, Marder, Galina, additional, Mohamed, Amr Ahmed El-Huesseini, additional, Monach, Paul, additional, Neyra, Nilda Roxana, additional, Niemer, Gregory W., additional, Niles, John, additional, Obi, Reginald, additional, Owens, Charles, additional, Parks, Deborah L., additional, Podoll, Amber S., additional, Rovin, Brad, additional, Sam, R, additional, Shergy, William Julius, additional, Silva, Arnold Lawrence, additional, Specks, Ulrich, additional, Spiera, Robert, additional, Springer, Jason M., additional, Striebich, Christopher Charles, additional, Swarup, Areena, additional, Thakar, Surabhi, additional, Tiliakos, Athan N., additional, Tsai, Yong, additional, Waguespack, Dia R., additional, and Chester Wasko, Mary, additional
- Published
- 2023
- Full Text
- View/download PDF
11. An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud’s phEnomenon (SUNSHINE survey)
- Author
-
Ingegnoli, Francesca, Ughi, Nicola, Dinsdale, Graham, Orenti, Annalisa, Boracchi, Patrizia, Allanore, Yannick, Foeldvari, Ivan, Sulli, Alberto, Cutolo, Maurizio, Smith, Vanessa, Herrick, Ariane L., Hij, Adrian, Sulli, Alberto, Nitsche, Alejandro, Vacca, Alessandra, Balbir-Gurman, Alexandra, Abdessemed, Amina, Vargas, Angelica, Valenzuela, Antonia, Makol, Ashima, Baranauskaite, Asta, Derfalvi, Beata, Serrano Benavente, Belén, Sozeri, Betul, Bica, Blanca E., Stamenkovic, Bojana, Mihai, Carina, Chizzolini, Carlo, Abud Mendoza, Carlos, de la Puente, Carlos, von Muhlen, Carlos, Bertolazzi, Chiara, Pain, Clare, Ickinger, Claudia, Ancuta, Codrina, Sunderkotter, Cord, Kayser, Cristiane, De Araujo, Daniel B., Launay, David, Khanna, Dinesh, Krasowska, Dorota, Veale, Douglas, Kaliterna, Dušanka M., Rosato, Edoardo, de Langhe, Ellen, Hachulla, Eric, Naredo, Esperanza, Loyo, Esthela, Alvarez Hernández, Everardo, Sztajnbok, Flavio, Boin, Francesco, Longo, Francisco J., van den Hoogen, Frank, Hernandez Molina, Gabriela, Riemekasten, Gabriela, Szucs, Gabriella, Moroncini, Gianluca, Fragoso Loyo, Hilda, Dobrev, Hristo, Janta, Iustina, Cracowski, Jean-Luc, Pauling, John, Akikusa, Jonathan, Sotoca Fernàndez, Jorge, Khan Ajaz, Kariem, Solanki, Kamal, Wierzba, Karol, Romanowska Próchnicka, Katarzyna, Rouster Stevens, Kelly, Belloli, Laura, Lewandowski, Laura, Santos, Lelita, Saketkoo, Lesley A., Ananyeva, Lidia, Beretta, Lorenzo, Michalska Jakubus, Małgorzata, Audisio, Marcelo J., Milchert, Marcin, Molina, Maria J., Moraes, Fontes Maria F., Terreri, Maria T., Puszczewicz, Mariusz, Barešić, Marko, Hufnagel, Markus, Mamani, Marta N., Gutierrez, Marwin, Curran, Megan, Hughes, Michael, Becker, Mike, Inanç, Murat, Petraitis, Mykolas, Juan Carlos, Nieto-Gonzàlez, Fathi, Nihal, Aktay Ayaz, Nuray, Distler, Oliver, Sander, Oliver, Ömer, Pamuk N., García dela Peña Lefebvre, Paloma, Caramaschi, Paola, Hasler, Paul, Ostojic, Predrag, Bečvář, Radim, Rodríguez, Reyna S. Tatiana, Lima, Rodrigo, Hesselstrand, Roger, Cimaz, Rolando, Irace, Rosaria, Petty, Ross, de Angelis, Rossella, Dobrota, Rucsandra, Payne-Poff, Sarah, Kubo, Satoshi, Guiducci, Serena, Popa, Serghei, Lambova, Sevdalina, Stebbings, Simon, Rednic, Simona, Yavuz, Sule, Benseler, Susa, Shevtsova, Tatzana, Daikeler, Thomas, Schmeiser, Tim, Frech, Tracy, Minier, Tünde, Müller Ladner, Ulf, Walker, Ulrich, Riccieri, Valeria, Vilela, Verônica, Hermann, Walter, Braun-Moscovici, Yolanda, Uziel, Yosef, Thierry, Zenone, and On behalf of the EULAR Study Group on Microcirculation in RheumaticDiseases
- Published
- 2017
- Full Text
- View/download PDF
12. Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis
- Author
-
Rentka, Aniko, Nagy, Annamaria, Harsfalvi, Jolan, Szucs, Gabriella, Szekanecz, Zoltan, Gesztelyi, Rudolf, Szodoray, Peter, and Kemeny-Beke, Adam
- Published
- 2017
- Full Text
- View/download PDF
13. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis
- Author
-
Gulyas, Katalin, Bodnar, Nora, Nagy, Zsofia, Szamosi, Szilvia, Horvath, Agnes, Vancsa, Andrea, Vegh, Edit, Szabo, Zoltan, Szucs, Gabriella, Szekanecz, Zoltan, and Szanto, Sandor
- Published
- 2014
14. Ophthalmological Manifestations and Tear Investigations in Systemic Sclerosis
- Author
-
Rentka, Aniko, primary, Koroskenyi, Krisztina, additional, Harsfalvi, Jolan, additional, Szekanecz, Zoltan, additional, Szucs, Gabriella, additional, Szodoray, Peter, additional, and Kemeny-Beke, Adam, additional
- Published
- 2017
- Full Text
- View/download PDF
15. Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis
- Author
-
Rentka, Aniko, Harsfalvi, Jolan, Szucs, Gabriella, Szekanecz, Zoltan, Szodoray, Peter, Koroskenyi, Krisztina, and Kemeny-Beke, Adam
- Published
- 2016
- Full Text
- View/download PDF
16. Hyperferritinemia is Associated with Serologic Antiphospholipid Syndrome in SLE Patients
- Author
-
Zandman-Goddard, Gisele, Orbach, Hedi, Agmon-Levin, Nancy, Boaz, Mona, Amital, Howard, Szekanecz, Zoltan, Szucs, Gabriella, Rovensky, Josef, Kiss, Emese, Corocher, Nadia, Doria, Andrea, Stojanovich, Ljudmila, Ingegnoli, Francesca, Meroni, Pier Luigi, Rozman, Blaz, Gomez-Arbesu, Jesus, Blank, Miri, and Shoenfeld, Yehuda
- Published
- 2013
- Full Text
- View/download PDF
17. Associations of vascular and bone status in arthritis patients
- Author
-
Pusztai, Anita, Hamar, Attila, Czokolyova, Monika, Gulyas, Katalin, Horvath, Agnes, Vegh, Edit, Petho, Zsofia, Szamosi, Szilvia, Balogh, Emese, Bodnar, Nora, Bodoki, Levente, Szentpetery, Agnes, Bhattoa, Harjit Pal, Kerekes, Gyorgy, Juhasz, Balazs, Szekanecz, Eva, Hodosi, Katalin, Domjan, Andrea, Szanto, Sandor, Raterman, Hennie G., Lems, Willem F., Szekanecz, Zoltan, Szucs, Gabriella, Pusztai, Anita, Hamar, Attila, Czokolyova, Monika, Gulyas, Katalin, Horvath, Agnes, Vegh, Edit, Petho, Zsofia, Szamosi, Szilvia, Balogh, Emese, Bodnar, Nora, Bodoki, Levente, Szentpetery, Agnes, Bhattoa, Harjit Pal, Kerekes, Gyorgy, Juhasz, Balazs, Szekanecz, Eva, Hodosi, Katalin, Domjan, Andrea, Szanto, Sandor, Raterman, Hennie G., Lems, Willem F., Szekanecz, Zoltan, and Szucs, Gabriella
- Abstract
Cardiovascular (CV) disease and osteoporosis (OP) have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Bone and vascular biomarkers and parameters along with the effect of 1-year anti-TNF therapy on these markers were assessed in order to determine correlations between vascular pathophysiology and bone metabolism in RA and AS. Thirty-six patients treated with etanercept or certolizumab pegol and 17 AS patients treated with ETN were included in a 12-month follow-up study. Bone and vascular markers were previously assessed by ELISA. Bone density was measured by DXA and quantitative CT (QCT). Flow-mediated vasodilation (FMD), common carotid intima-media thickness (IMT) and pulse-wave velocity (PWV) were assessed by ultrasound. Multiple correlation analyses indicated associations between bone and vascular markers. Osteoprotegerin, sclerostin and cathepsin K were significantly associated with FMD, IMT and PWV, respectively (p < 0.05). Moreover, total and trabecular BMD determined by QCT inversely correlated with IMT (p < 0.05). On the other hand, among vascular parameters, platelet-derived growth factor BB and IMT correlated with DXA femoral and QCT total BMD, respectively (p < 0.05). In the RM-ANOVA analysis, anti-TNF treatment together with baseline osteocalcin, procollagen 1 N-terminal propeptide (P1NP) or vitamin D3 levels determined one-year changes in IMT (p < 0.05). In the MANOVA analysis, baseline disease activity indices (DAS28, BASDAI), the one-year changes in these indices, as well as CRP exerted effects on multiple correlations between bone and vascular markers (p < 0.05). As the pattern of interactions between bone and vascular biomarkers differed between baseline and after 12 months, anti-TNF therapy influenced these associations. We found a great number of correlations in our RA and AS patients undergoing anti-TNF therapy. Some of the bone markers have been associated with vascular pathophysiology, while some
- Published
- 2021
- Full Text
- View/download PDF
18. Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients
- Author
-
Juhasz, Balazs, Gulyas, Katalin, Horvath, Agnes, Vegh, Edit, Pusztai, Anita, Szentpetery, Agnes, Petho, Zsofia, Bodnar, Nora, Hamar, Attila, Bodoki, Levente, Bhattoa, Harjit Pal, Szekanecz, Eva, Hodosi, Katalin, Domjan, Andrea, Szamosi, Szilvia, Horvath, Csaba, Szanto, Sandor, Szucs, Gabriella, Raterman, Hennie G., Lems, Willem F., FitzGerald, Oliver, Szekanecz, Zoltan, Juhasz, Balazs, Gulyas, Katalin, Horvath, Agnes, Vegh, Edit, Pusztai, Anita, Szentpetery, Agnes, Petho, Zsofia, Bodnar, Nora, Hamar, Attila, Bodoki, Levente, Bhattoa, Harjit Pal, Szekanecz, Eva, Hodosi, Katalin, Domjan, Andrea, Szamosi, Szilvia, Horvath, Csaba, Szanto, Sandor, Szucs, Gabriella, Raterman, Hennie G., Lems, Willem F., FitzGerald, Oliver, and Szekanecz, Zoltan
- Abstract
Introduction Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with osteoporosis. There have not been many peripheral quantitative computed tomography (QCT) studies in patients receiving biologics. We assessed volumetric and areal bone mineral density (BMD) by forearm QCT and dual-energy X-ray absorptiometry (DXA), respectively in addition to laboratory biomarkers in these arthritides. Methods Forty RA and AS patients treated with either etanercept (ETN) or certolizumab pegol (CZP) were undergoing follow-ups for one year. Volumetric and areal BMD, as well as parathyroid hormone (PTH), osteocalcin, RANKL, 25-hydroxyvitamin D (VITD), P1NP, CTX, sclerostin (SOST), Dickkopf 1 (DKK-1) and cathepsin K (CATHK) were determined. Results We did not observe any further bone loss during the 12-month treatment period. Volumetric and areal BMD showed significant correlations with each other (p<0.017 after Bonferroni's correction). Trabecular QCT BMD at baseline (p=0.015) and cortical QCT BMD after 12 months (p=0.005) were inversely determined by disease activity at baseline in the full cohort. Trabecular QCT BMD at baseline also correlated with CTX (p=0.011). In RA, CRP negatively (p=0.014), while SOST positively (p=0.013) correlated with different QCT parameters. In AS, RANKL at baseline (p=0.014) and after 12 months (p=0.007) correlated with cortical QCT BMD. In the full cohort, 12-month change in QTRABBMD was related to TNF inhibition together with elevated VITD-0 levels (p=0.031). Treatment and lower CATHK correlated with QCORTBMD changes (p=0.006). In RA, TNF inhibition together with VITD-0 (p<0.01) or CATHK-0 (p=0.002), while in AS, treatment and RANKL-0 (p<0.05) determined one-year changes in QCT BMD. Conclusions BMD as determined by QCT did not change over one year of anti-TNF treatment. Disease activity, CATHK, RANKL and VITD may be associated with the effects of anti-TNF treatment on QCT BMD changes. RA and AS may differ in this respect.
- Published
- 2021
- Full Text
- View/download PDF
19. Prolactin and Autoimmunity: Hyperprolactinemia Correlates with Serositis and Anemia in SLE Patients
- Author
-
Orbach, Hedi, Zandman-Goddard, Gisele, Boaz, Mona, Agmon-Levin, Nancy, Amital, Howard, Szekanecz, Zoltan, Szucs, Gabriella, Rovensky, Josef, Kiss, Emese, Doria, Andrea, Ghirardello, Anna, Gomez-Arbesu, Jesus, Stojanovich, Ljudmila, Ingegnoli, Francesca, Meroni, Pier Luigi, Rozman, Blaz’, Blank, Miri, and Shoenfeld, Yehuda
- Published
- 2012
- Full Text
- View/download PDF
20. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: Associations with organ manifestations, immunolaboratory markers and disease activity indices
- Author
-
Szekanecz, Éva, Szűcs, Gabriella, Szekanecz, Zoltán, Tarr, Tünde, Antal-Szalmás, Péter, Szamosi, Szilvia, Szántó, János, and Kiss, Emese
- Published
- 2008
- Full Text
- View/download PDF
21. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis
- Author
-
Gulyas, Katalin, Horvath, Agnes, Vegh, Edit, Pusztai, Anita, Szentpetery, Agnes, Petho, Zsofia, Vancsa, Andrea, Bodnar, Nora, Csomor, Peter, Hamar, Attila, Bodoki, Levente, Bhattoa, Harjit Pal, Juhasz, Balazs, Nagy, Zoltan, Hodosi, Katalin, Karosi, Tamas, FitzGerald, Oliver, Szucs, Gabriella, Szekanecz, Zoltan, Szamosi, Szilvia, Szanto, Sandor, Gulyas, Katalin, Horvath, Agnes, Vegh, Edit, Pusztai, Anita, Szentpetery, Agnes, Petho, Zsofia, Vancsa, Andrea, Bodnar, Nora, Csomor, Peter, Hamar, Attila, Bodoki, Levente, Bhattoa, Harjit Pal, Juhasz, Balazs, Nagy, Zoltan, Hodosi, Katalin, Karosi, Tamas, FitzGerald, Oliver, Szucs, Gabriella, Szekanecz, Zoltan, Szamosi, Szilvia, and Szanto, Sandor
- Abstract
Objectives Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with generalized and localized bone loss. We conducted a comprehensive study using imaging (dual-energy X-ray absorptiometry, DXA) and laboratory biomarkers in order to determine bone health and to study the effects of anti-tumor necrosis factor (TNF) biologics in RA and AS. Patients and methods Thirty-six RA and 17 AS patients undergoing 1-year etanercept (ETN) or certolizumab-pegol (CZP) therapy were studied. Bone density was assessed by DXA at baseline and after 12 months. Serum C-reactive protein (CRP), calcium, phosphate, parathyroid hormone (PTH), vitamin D3, osteocalcin, procollagen type I N-propeptide (P1NP), C-terminal telopeptide (βCTX), osteoprotegerin, sclerostin (SOST), Dickkopf-1 (DKK-1), soluble receptor activator nuclear kappa B ligand (sRANKL), and cathepsin K (cathK) levels were determined at baseline and after 6 and 12 months. Results TNF-α inhibition was clinically effective. Anti-TNF-α halted further bone loss over 1 year. In general, anti-TNF therapy significantly increased P1NP, SOST levels, and the P1NP/βCTX ratios, while decreased DKK-1 and CathK production at different time points in most patient subsets. In the full cohort and in RA, baseline and/or 12-month bone mineral density (BMD) at multiple sites exerted inverse relationships with CRP and βCTX, and positive correlation with SOST. In AS, L2-4 BMD after 1-year biologic therapy inversely correlated with baseline βCTX, while femoral neck BMD rather showed inverse correlations with CRP. Conclusions Anti-TNF therapy slowed down generalized bone loss, in association with clinical improvements, in both diseases. TNF blockade may enhance bone formation and suppress joint destruction. Anti-TNF therapy may act inversely on DKK-1 and SOST. Independent predictors of BMD were SOST and βCTX in RA, whilst CRP in AS.
- Published
- 2020
- Full Text
- View/download PDF
22. Prolactin and Autoimmunity
- Author
-
Orbach, Hedi, Zandman-Goddard, Gisele, Boaz, Mona, Agmon-Levin, Nancy, Amital, Howard, Szekanecz, Zoltan, Szucs, Gabriella, Rovensky, Josef, Kiss, Emese, Doria, Andrea, Ghirardello, Anna, Gomez-Arbesu, Jesus, Stojanovich, Ljudmila, Ingegnoli, Francesca, Meroni, Pier Luigi, Rozman, Blazʼ, Blank, Miri, and Shoenfeld, Yehuda
- Published
- 2012
- Full Text
- View/download PDF
23. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
- Author
-
Tyndall, Anthony J, Bannert, Bettina, Vonk, Madelon, Airò, Paolo, Cozzi, Franco, Carreira, Patricia E, Bancel, Dominique Farge, Allanore, Yannick, Müller-Ladner, Ulf, Distler, Oliver, Iannone, Florenzo, Pellerito, Raffaele, Pileckyte, Margarita, Miniati, Irene, Ananieva, Lidia, Gurman, Alexandra Balbir, Damjanov, Nemanja, Mueller, Adelheid, Valentini, Gabriele, Riemekasten, Gabriela, Tikly, Mohammed, Hummers, Laura, Henriques, Maria JS, Caramaschi, Paola, Scheja, Agneta, Rozman, Blaz, Ton, Evelien, Kumánovics, Gábor, Coleiro, Bernard, Feierl, Eva, Szucs, Gabriella, Von Mühlen, Carlos Alberto, Riccieri, Valeria, Novak, Srdan, Chizzolini, Carlo, Kotulska, Anna, Denton, Christopher, Coelho, Paulo C, Kötter, Ina, Simsek, Ismail, de la Pena Lefebvre, Paloma García, Hachulla, Eric, Seibold, James R, Rednic, Simona, Štork, Jiří, Morovic-Vergles, Jadranka, and Walker, Ulrich A
- Published
- 2010
- Full Text
- View/download PDF
24. Decreased lymphatic vessel counts in patients with systemic sclerosis: Association with fingertip ulcers
- Author
-
Akhmetshina, Alfiya, Beer, Jürgen, Zwerina, Karin, Englbrecht, Matthias, Palumbo, Katrin, Dees, Clara, Reich, Nicole, Zwerina, Jochen, Szucs, Gabriella, Gusinde, Johannes, Nevskaya, Tatiana, Distler, Oliver, Kerjaschki, Dontscho, Schett, Georg, and Distler, Jörg H. W.
- Published
- 2010
- Full Text
- View/download PDF
25. Rho-Associated Kinases Are Crucial for Myofibroblast Differentiation and Production of Extracellular Matrix in Scleroderma Fibroblasts
- Author
-
Akhmetshina, Alfiya, Dees, Clara, Pileckyte, Margarita, Szucs, Gabriella, Spriewald, Bernd M., Zwerina, Jochen, Distler, Oliver, Schett, Georg, and Distler, Jörg H. W.
- Published
- 2008
26. Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis
- Author
-
Gulyas, Katalin, Horvath, Agnes, Vegh, Edit, Pusztai, Anita, Szentpetery, Agnes, Petho, Zsofia, Vancsa, Andrea, Bodnar, Nora, Csomor, Peter, Hamar, Attila, Bodoki, Levente, Bhattoa, Harjit Pal, Juhasz, Balazs, Nagy, Zoltan, Hodosi, Katalin, Karosi, Tamas, FitzGerald, Oliver, Szucs, Gabriella, Szekanecz, Zoltan, Szamosi, Szilvia, and Szanto, Sandor
- Subjects
Adult ,Male ,Bone loss ,Sclerostin ,Biologics ,Etanercept ,DKK-1 ,Arthritis, Rheumatoid ,Young Adult ,Absorptiometry, Photon ,Bone Density ,Spondyloarthritis ,Humans ,Spondylitis, Ankylosing ,Rheumatoid arthritis ,Rheumatology and Autoimmunity ,Adaptor Proteins, Signal Transducing ,Aged ,Aged, 80 and over ,Reumatologi och inflammation ,JAK inhibitors ,Syndesmophyte ,Osteoprotegerin ,RANKL ,Middle Aged ,C-Reactive Protein ,Erosion ,Certolizumab Pegol ,Osteoporosis ,Intercellular Signaling Peptides and Proteins ,Regression Analysis ,Female ,Tumor Necrosis Factor Inhibitors ,Biomarkers - Abstract
Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with generalized and localized bone loss. We conducted a comprehensive study using imaging (dual-energy X-ray absorptiometry, DXA) and laboratory biomarkers in order to determine bone health and to study the effects of anti-tumor necrosis factor (TNF) biologics in RA and AS.Thirty-six RA and 17 AS patients undergoing 1-year etanercept (ETN) or certolizumab-pegol (CZP) therapy were studied. Bone density was assessed by DXA at baseline and after 12 months. Serum C-reactive protein (CRP), calcium, phosphate, parathyroid hormone (PTH), vitamin D3, osteocalcin, procollagen type I N-propeptide (P1NP), C-terminal telopeptide (βCTX), osteoprotegerin, sclerostin (SOST), Dickkopf-1 (DKK-1), soluble receptor activator nuclear kappa B ligand (sRANKL), and cathepsin K (cathK) levels were determined at baseline and after 6 and 12 months.TNF-α inhibition was clinically effective. Anti-TNF-α halted further bone loss over 1 year. In general, anti-TNF therapy significantly increased P1NP, SOST levels, and the P1NP/βCTX ratios, while decreased DKK-1 and CathK production at different time points in most patient subsets. In the full cohort and in RA, baseline and/or 12-month bone mineral density (BMD) at multiple sites exerted inverse relationships with CRP and βCTX, and positive correlation with SOST. In AS, L2-4 BMD after 1-year biologic therapy inversely correlated with baseline βCTX, while femoral neck BMD rather showed inverse correlations with CRP.Anti-TNF therapy slowed down generalized bone loss, in association with clinical improvements, in both diseases. TNF blockade may enhance bone formation and suppress joint destruction. Anti-TNF therapy may act inversely on DKK-1 and SOST. Independent predictors of BMD were SOST and βCTX in RA, whilst CRP in AS.Key Points• One-year anti-TNF therapy halted generalized bone loss in association with clinical improvement in arthritides.• Anti-TNF therapy may inversely act on DKK-1 and SOST.• Independent predictors of BMD were SOST and βCTX in RA, while CRP in AS.
- Published
- 2019
27. Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma Trials and Research cohort of patients with systemic sclerosis
- Author
-
Sobanski, Vincent, Giovannelli, Jonathan, Allanore, Yannick, Riemekasten, Gabriela, Airo, Paolo, Vettori, Serena, Cozzi, Franco, Distler, Oliver, Matucci-Cerinic, Marco, Denton, Christopher, Launay, David, Hachulla, Eric, Cerinic, Marco Matucci, Guiducci, Serena, Walker, Ulrich, Kyburz, Diego, Lapadula, Giovanni, Iannone, Florenzo, Maurer, Britta, Jordan, Suzana, Becvar, Radim, Sierakowsky, Stanislaw, Bielecka, Otylia Kowal, Cutolo, Maurizio, Sulli, Alberto, Valentini, Gabriele, Cuomo, Giovanna, Siegert, Elise, Rednic, Simona, Nicoara, Ileana, Kahan, Andre, Vlachoyiannopoulos, Panayiotis, Montecucco, Carlo, Caporali, Roberto, Stork, Jiri, Inanc, Murat, Carreira, Patricia E, Novak, Srdan, Czirjak, Laszlo, Varju, Cecilia, Chizzolini, Carlo, Kucharz, Eugene J, Kotulska, Anna, Kopec-Medrek, Magdalena, Widuchowska, Malgorzata, Rozman, Blaz, Mallia, Carmel, Coleiro, Bernard, Gabrielli, Armando, Farge, Dominique, Wu, Chen, Marjanovic, Zora, Faivre, Helene, Hij, Darin, Dhamadi, Roza, Hesselstrand, Roger, Wollheim, Frank, Wuttge, Dirk M, Andreasson, Kristofer, Martinovic, Duska, Balbir-Gurman, Alexandra, Braun-Moscovici, Yolanda, Trotta, Francesco, Lo Monaco, Andrea, Hunzelmann, Nicolas, Pellerito, Raffaele, Bambara, Lisa Maria, Caramaschi, Paola, Morovic-Vergles, Jadranka, Black, Carol, Damjanov, Nemanja, Henes, Joerg, Ortiz Santamaria, Vera, Heitmann, Stefan, Krasowska, Dorota, Seidel, Matthias, Hasler, Paul, Burkhardt, Harald, Himsel, Andrea, Bajocchi, Gianluigi, Nuova, Arcispedale Santa Maria, Salvador, Maria Joao, Pereira Da Silva, Jose Antonio, Stamenkovic, Bojana, Stankovic, Aleksandra, Selmi, Carlo Francesco, De Santis, Maria, Marasini, Bianca, Tikly, Mohammed, Ananieva, Lidia P, Denisov, Lev N, Mueller-Ladner, Ulf, Frerix, Marc, Tarner, Ingo, Scorza, Raffaella, Puppo, Francesco, Engelhart, Merete, Strauss, Gitte, Nielsen, Henrik, Damgaard, Kirsten, Szucs, Gabriella, Szamosi, Szilvia, Zea Mendoza, Antonio, de la Puente, Carlos, Sifuentes Giraldo, Walter Alberto, Midtvedt, Oyvind, Reiseter, Silje, Garen, Torhild, Valesini, Guido, Riccieri, Valeria, Ionescu, Ruxandra Maria, Opris, Daniela, Groseanu, Laura, Wigley, Fredrick M, Cornateanu, Roxana Sfrent, Ionitescu, Razvan, Gherghe, Ana Maria, Soare, Alina, Gorga, Marilena, Bojinca, Mihai, Mihai, Carina, Milicescu, Mihaela, Sunderkoetter, Cord, Kuhn, Annegret, Sandorfi, Nora, Schett, Georg, Distler, Joerg HW, Beyer, Christian, Meroni, Pierluigi, Ingegnoli, Francesca, Mouthon, Luc, De Keyser, Filip, Smith, Vanessa, Cantatore, Francesco Paolo, Corrado, Ada, Ullman, Susanne, Iversen, Line, von Muehlen, Carlos Alberto, Bohn, Jussara Marilu, Lonzetti, Lilian Scussel, Pozzi, Maria Rosa, Eyerich, Kilian, Hein, Ruediger, Knott, Elisabeth, Wiland, Piotr, Szmyrka-Kaczmarek, Magdalena, Sokolik, Renata, Morgiel, Ewa, Madej, Marta, Houssiau, Frederic A, Jose Alegre-Sancho, Juan, Krummel-Lorenz, Brigitte, Saar, Petra, Aringer, Martin, Guenther, Claudia, Westhovens, Rene, de Langhe, Ellen, Lenaerts, Jan, Anic, Branimir, Baresic, Marko, Mayer, Miroslav, Uprus, Maria, Otsa, Kati, Yavuz, Sule, Granel, Brigitte, Radominski, Sebastiao Cezar, Mueller, Carolina de Souza, Azevedo, Valderilio Feijo, Jimenez, Sergio, Busquets, Joanna, Agachi, Svetlana, Groppa, Liliana, Chiaburu, Lealea, Russu, Eugen, Popa, Sergei, Zenone, Thierry, Pileckyte, Margarita, Stebbings, Simon, Highton, John, Mathieu, Alessandro, Vacca, Alessandra, Sampaio-Barros, Percival D, Yoshinari, Natalino H, Marangoni, Roberta G, Martin, Patricia, Fuocco, Luiza, Stamp, Lisa, Chapman, Peter, O'Donnell, John, Solanki, Kamal, Doube, Alan, Veale, Douglas, O'Rourke, Marie, Loyo, Esthela, Li, Mengtao, Mohamed, Walid Ahmed Abdel Atty, Rosato, Edoardo, Amoroso, Antonio, Gigante, Antonietta, Oksel, Fahrettin, Yargucu, Figen, Tanaseanu, Cristina-Mihaela, Popescu, Monica, Dumitrascu, Alina, Tiglea, Isabela, Foti, Rosario, Chirieac, Rodica, Ancuta, Codrina, Furst, Daniel E, Villiger, Peter, Adler, Sabine, van Laar, Jacob, Kayser, Cristiane, Eduardo, Andrade Luis C, Fathi, Nihal, Hassanien, Manal, de la Pena Lefebvre, Paloma Garcia, Rodriguez Rubio, Silvia, Valero Exposito, Marta, Sibilia, Jean, Chatelus, Emmanuel, Gottenberg, Jacques Eric, Chifflot, Helene, Litinsky, Ira, Emery, Paul, Buch, Maya, Del Galdo, Francesco, Venalis, Algirdas, Butrimiene, Irena, Venalis, Paulius, Rugiene, Rita, Karpec, Diana, Saketkoo, Lesley Ann, Lasky, Joseph A, Kerzberg, Eduardo, Montoya, Fabiana, Cosentino, Vanesa, Limonta, Massimiliano, Brucato, Antonio Luca, Lupi, Elide, Rosner, Itzhak, Rozenbaum, Michael, Slobodin, Gleb, Boulman, Nina, Rimar, Doron, Couto, Maura, Spertini, Francois, Ribi, Camillo, Buss, Guillaume, Kahl, Sarah, Hsu, Vivien M, Chen, Fei, McCloskey, Deborah, Malveaux, Halina, Pasquali, Jean Louis, Martin, Thierry, Gorse, Audrey, Guffroy, Aurelien, Poindron, Vincent, EUSTAR Collaborators, Guiducci, S., Walker, U., Kyburz, D., Lapadula, G., Iannone, F., Maurer, B., Jordan, S., Becvar, R., Sierakowsky, S., Kowal Bielecka, O., Cutolo, M., Sulli, A., Valentini, G., Cuomo, G., Siegert, E., Rednic, S., Nicoara, I., Kahan, A., Vlachoyiannopoulos, P., Montecucco, C., Caporali, R., Stork, J., Inanc, M., Carreira, P.E., Novak, S., Czirják, L., Varju, C., Chizzolini, C., Kucharz, E.J., Kotulska, A., Kopec-Medrek, M., Widuchowska, M., Rozman, B., Mallia, C., Coleiro, B., Gabrielli, A., Farge, D., Wu, C., Marjanovic, Z., Faivre, H., Hij, D., Dhamadi, R., Airò, P., Hesselstrand, R., Wollheim, F., Wuttge, D.M., Andréasson, K., Martinovic, D., Balbir-Gurman, A., Braun-Moscovici, Y., Trotta, F., Lo Monaco, A., Hunzelmann, N., Pellerito, R., Mauriziano, O., Maria Bambara, L., Caramaschi, P., Morovic-Vergles, J., Black, C., Damjanov, N., Henes, J., Ortiz Santamaria, V., Heitmann, S., Krasowska, D., Seidel, M., Hasler, P., Burkhardt, H., Himsel, A., Bajocchi, G., Maria Nuova, A.S., João Salvador, M., Pereira Da Silva, J.A., Stamenkovic, B., Stankovic, A., Francesco Selmi, C., De Santis, M., Marasini, B., Tikly, M., Ananieva, L.P., Denisov, L.N., Müller-Ladner, U., Frerix, M., Tarner, I., Scorza, R., Puppo, F., Engelhart, M., Strauss, G., Nielsen, H., Damgaard, K., Szücs, G., Szamosi, S., Zea Mendoza, A., de la Puente, C., Sifuentes Giraldo, W.A., Midtvedt, Ø., Reiseter, S., Garen, T., Valesini, G., Riccieri, V., Maria Ionescu, R., Opris, D., Groseanu, L., Wigley, F.M., Sfrent Cornateanu, R., Ionitescu, R., Maria Gherghe, A., Soare, A., Gorga, M., Bojinca, M., Mihai, C., Milicescu, M., Sunderkötter, C., Kuhn, A., Sandorfi, N., Schett, G., Distler, J.H., Beyer, C., Meroni, P., Ingegnoli, F., Mouthon, L., De Keyser, F., Smith, V., Paolo Cantatore, F., Corrado, A., Ullman, S., Iversen, L., Alberto von Mühlen, C., Marilu Bohn, J., Scussel Lonzetti, L., Rosa Pozzi, M., Eyerich, K., Hein, R., Knott, E., Wiland, P., Szmyrka-Kaczmarek, M., Sokolik, R., Morgiel, E., Madej, M., Houssiau, F.A., Jose Alegre-Sancho, J., Krummel-Lorenz, B., Saar, P., Aringer, M., Günther, C., Westhovens, R., de Langhe, E., Lenaerts, J., Anic, B., Baresic, M., Mayer, M., Üprus, M., Otsa, K., Yavuz, S., Granel, B., Cezar Radominski, S., de Souza Müller, C., Azevedo, V.F., Jimenez, S., Busquets, J., Agachi, S., Groppa, L., Chiaburu, L., Russu, E., Popa, S., Zenone, T., Pileckyte, M., Stebbings, S., Highton, J., Mathieu, A., Vacca, A., Sampaio-Barros, P.D., Yoshinari, N.H., Marangoni, R.G., Martin, P., Fuocco, L., Stamp, L., Chapman, P., O'Donnell, J., Solanki, K., Doube, A., Veale, D., O'Rourke, M., Loyo, E., Li, M., Abdel Atty Mohamed, W.A., Rosato, E., Amoroso, A., Gigante, A., Oksel, F., Yargucu, F., Tanaseanu, C.M., Popescu, M., Dumitrascu, A., Tiglea, I., Foti, R., Chirieac, R., Ancuta, C., Furst, D.E., Villiger, P., Adler, S., van Laar, J., Kayser, C., Eduardo C, A.L., Fathi, N., Hassanien, M., de la Peña Lefebvre, P.G., Rodriguez Rubio, S., Valero Exposito, M., Sibilia, J., Chatelus, E., Gottenberg, J.E., Chifflot, H., Litinsky, I., Emery, P., Buch, M., Del Galdo, F., Venalis, A., Butrimiene, I., Venalis, P., Rugiene, R., Karpec, D., Ann Saketkoo, L., Lasky, J.A., Kerzberg, E., Montoya, F., Cosentino, V., Limonta, M., Luca Brucato, A., Lupi, E., Rosner, I., Rozenbaum, M., Slobodin, G., Boulman, N., Rimar, D., Couto, M., Spertini, F., Ribi, C., Buss, G., Kahl, S., Hsu, V.M., Chen, F., McCloskey, D., Malveaux, H., Louis Pasquali, J., Martin, T., Gorse, A., Guffroy, A., Poindron, V., and Chizzolini, Carlo
- Subjects
0301 basic medicine ,Male ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences ,Databases, Factual ,systemic sclerosis ,SUBSETS ,Disease ,Severity of Illness Index ,Scleroderma ,DISEASE ,0302 clinical medicine ,Medicine and Health Sciences ,Immunology and Allergy ,Cluster Analysis ,CRITERIA ,Prospective Studies ,Prospective cohort study ,skin and connective tissue diseases ,integumentary system ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti ,Adult ,Aged ,Autoantibodies/blood ,Europe/epidemiology ,Female ,Humans ,Middle Aged ,Phenotype ,Prognosis ,Scleroderma, Diffuse/blood ,Scleroderma, Diffuse/epidemiology ,Scleroderma, Diffuse/pathology ,Scleroderma, Limited/blood ,Scleroderma, Limited/epidemiology ,Scleroderma, Limited/pathology ,Scleroderma, Systemic/blood ,Scleroderma, Systemic/epidemiology ,Scleroderma, Systemic/pathology ,Connective tissue disease ,ddc ,Europe ,MANIFESTATIONS ,Cohort ,Life Sciences & Biomedicine ,medicine.medical_specialty ,Immunology ,PROFILE ,CLASSIFICATION ,03 medical and health sciences ,Rheumatology ,Scleroderma, Limited ,Internal medicine ,Severity of illness ,medicine ,Autoantibodies ,030203 arthritis & rheumatology ,Science & Technology ,Scleroderma, Systemic ,business.industry ,Autoantibody ,Systemic sclerosis (SSc) ,medicine.disease ,030104 developmental biology ,Scleroderma, Diffuse ,business - Abstract
OBJECTIVE: Systemic sclerosis (SSc) is a heterogeneous connective tissue disease that is typically subdivided into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) depending on the extent of skin involvement. This subclassification may not capture the entire variability of clinical phenotypes. The European Scleroderma Trials and Research (EUSTAR) database includes data on a prospective cohort of SSc patients from 122 European referral centers. This study was undertaken to perform a cluster analysis of EUSTAR data to distinguish and characterize homogeneous phenotypes without any a priori assumptions, and to examine survival among the clusters obtained. METHODS: A total of 11,318 patients were registered in the EUSTAR database, and 6,927 were included in the study. Twenty-four clinical and serologic variables were used for clustering. RESULTS: Clustering analyses provided a first delineation of 2 clusters showing moderate stability. In an exploratory attempt, we further characterized 6 homogeneous groups that differed with regard to their clinical features, autoantibody profile, and mortality. Some groups resembled usual dcSSc or lcSSc prototypes, but others exhibited unique features, such as a majority of lcSSc patients with a high rate of visceral damage and antitopoisomerase antibodies. Prognosis varied among groups and the presence of organ damage markedly impacted survival regardless of cutaneous involvement. CONCLUSION: Our findings suggest that restricting subsets of SSc patients to only those based on cutaneous involvement may not capture the complete heterogeneity of the disease. Organ damage and antibody profile should be taken into consideration when individuating homogeneous groups of patients with a distinct prognosis. ispartof: ARTHRITIS & RHEUMATOLOGY vol:71 issue:9 pages:1553-1570 ispartof: location:United States status: published
- Published
- 2019
28. Novel Biomarkers in Autoimmune Diseases: Prolactin, Ferritin, Vitamin D, and TPA Levels in Autoimmune Diseases
- Author
-
ORBACH, HEDI, ZANDMAN-GODDARD, GISELE, AMITAL, HOWARD, BARAK, VIVIAN, SZEKANECZ, ZOLTAN, SZUCS, GABRIELLA, DANKO, KATALIN, NAGY, ENDRE, CSEPANY, TUNDE, CARVALHO, JOZELIO F., DORIA, ANDREA, and SHOENFELD, YEHUDA
- Published
- 2007
29. A Wide Spectrum of Ocular Manifestations Signify Patients with Systemic Sclerosis
- Author
-
Szucs, Gabriella, primary, Szekanecz, Zoltan, additional, Aszalos, Zsuzsa, additional, Gesztelyi, Rudolf, additional, Zsuga, Judit, additional, Szodoray, Peter, additional, and Kemeny-Beke, Adam, additional
- Published
- 2019
- Full Text
- View/download PDF
30. Off-label use of rituximab for systemic lupus erythematosus in Europe
- Author
-
Ryden-Aulin, Monica, Boumpas, Dimitrios, Bultink, Irene, Rubio, Jose Luis Callejas, Caminal-Montero, Luis, Castro, Antoni, Colodro Ruiz, Agustin, Doria, Andrea, Domer, Thomas, Gonzalez-Echavarri, Cristina, Gremese, Elisa, Houssiau, Frederic A., Huizinga, Tom, Inana, Murat, Isenberg, David, Luliano, Annamaria, Jacobsen, Soren, Jimenez-Alonso, Juan, Kovacs, Laszlo, Mariette, Xavier, Mosca, Marta, Nived, Ola, Oristrell, Joaquim, Ramos-Casals, Manuel, Rascon, Javier, Ruiz-Irastorza, Guillermo, Saez-Comet, Luis, Salvador Cervello, Gonzalo, Cervello, Gonzalo Salvador, Sebastiani, Gian Domenico, Squatrito, Danilo, Szucs, Gabriella, Voskuyl, Alexandre, van Vollenhoven, Ronald, Rheumatology, AII - Inflammatory diseases, [Ryden-Aulin, Monica] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Unit Clin Therapy Res, Stockholm, Sweden, [van Vollenhoven, Ronald] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Unit Clin Therapy Res, Stockholm, Sweden, [Boumpas, Dimitrios] Natl & Kapodestrian Univ Athens, Attikon Univ Hosp, Joint Acad Rheumatol Program, Med Sch, Athens, Greece, [Boumpas, Dimitrios] Natl & Kapodestrian Univ Athens, Attikon Univ Hosp, Dept Med 4, Med Sch, Athens, Greece, [Bultink, Irene] Amsterdam Rheumatol & Immunol Ctr, Tepartment Rheumatol, Amsterdam, Netherlands, [Rubio, Jose Luis Callejas] Hosp San Cecilio, Unit Autoimmune Dis, Granada, Spain, [Caminal-Montero, Luis] Hosp Univ Cent Asturias, Internal Med Dept, Autoimmune System Dis Unit, Oviedo, Spain, [Castro, Antoni] Rovira & Virgili Univ URV, Univ Hosp Sant Joan Reus, lnternal Med Dept Univ, IISPV, Reus, Spain, [Colodro Ruiz, Agustin] Pasaje Nueva Victoria,2,2do C, Jaen, Spain, [Doria, Andrea] Univ Padua, Dept Med, Rheumatol Unit, Padua, Italy, [Domer, Thomas] Charite Univ Med Berlin, Dept Med Rheumatol & Clin Immunol, Berlin, Germany, [Gonzalez-Echavarri, Cristina] Univ Basque Country, Cruces Univ Hosp, BioCruces Hlth Res Inst, Autoimmune Dis Res Unit,Dept Internal Med, Baracaldo, Spain, [Ruiz-Irastorza, Guillermo] Univ Basque Country, Cruces Univ Hosp, BioCruces Hlth Res Inst, Autoimmune Dis Res Unit,Dept Internal Med, Baracaldo, Spain, [Gremese, Elisa] Univ Cattolica Sacro Cuore, Inst Rheumatol & Affine Sci IRSA, Rome, Italy, [Houssiau, Frederic A.] Catholic Univ Louvain, Pole Pathol Rhumatismales Inflammatoires & Syst, Clin Univ St Luc, Serv Rhumatol, Brussels, Belgium, [Huizinga, Tom] Leiden Univ, Med Ctr, Dept Rheumatol, C1-41, Leiden, Netherlands, [Inana, Murat] Istanbul Univ, Istanbul Fac Med, Dept Internal Med, Div Rheumatol, Istanbul, Turkey, [Isenberg, David] UCL, Rayne Bldg, London, England, [Luliano, Annamaria] San Camillo Hosp, Rheumatol Unit, Rome, Italy, [Jacobsen, Soren] Univ Copenhagen, Rigshosp, Ctr Rheumatol & Spine Dis, Copenhagen Lupus & Vasculitis Clin, Copenhagen, Denmark, [Jimenez-Alonso, Juan] Univ Virgen Nieves Hosp, lnternal Dept, Granada, Spain, [Kovacs, Laszlo] Univ Szeged, Albert Szent Gyorgyi Hlth Ctr, Fac Med, Dept Rheumatol, Szeged, Hungary, [Mariette, Xavier] Univ Paris Sud, Hopitaux Univ Paris Sud, Rhumatol Responsable Unite Rech Clin, INSERM U1184, Paris, France, [Mosca, Marta] Rheumatol Unit, Pisa, Italy, [Nived, Ola] Skane Univ Hosp, Rheumatol Clin, Lund, Sweden, [Oristrell, Joaquim] Univ Autonoma Barcelona, Hosp Sabadell, Internal Med Dept, Catalunya, Spain, [Ramos-Casals, Manuel] CELLEX IDIBAPS, Josep Font Autoimmune Lab, ICMiD, Dept Autoimmune Dis, Barcelona, Spain, [Rascon, Javier] Carrer Sabateres, 9-1,Alare, Islas Baleares, Spain, [Saez-Comet, Luis] Hosp Univ Miguel Servet Zaragoza, Unidad Enfermedades Autoinmunes Sistem, Paseo Isabel Catolica, Zaragoza, Spain, [Salvador Cervello, Gonzalo] Hosp Univ & Politecn La Fe, Inmunopathol & Autoimmune Area, Dept Internal Med, Valencia, Spain, [Sebastiani, Gian Domenico] Osped San Camillo, UOC Reumatol, Circonvallaz Gianicolense 87, Rome, Italy, [Squatrito, Danilo] Univ Florence, Dept Sperimental & Clin Med, Florence, Italy, [Szucs, Gabriella] Univ Debrecen, Inst Med, Dept Rheumatol, Debrecen, Hungary, [Voskuyl, Alexandre] Vrije Univ Amsterdam, Med Ctr, Amsterdam Rheumatol & Immunol Ctr ARC, Amsterdam, Netherlands, [van Vollenhoven, Ronald] Karolinska Univ Hosp Stockholm, Rheumatol Clin, Stockholm, Sweden, [van Vollenhoven, Ronald] Amsterdam Rheumatol & Immunol Ctr ARC, AMC Mail F4-105, Amsterdam, Netherlands, MSD, Lilly Netherlands, Roche, UCB, Sanofi, and RvV
- Subjects
medicine.medical_specialty ,Disease duration ,Immunology ,Lupus nephritis ,DMARDs (biologic) ,Klinikai orvostudományok ,Off-label use ,Systemic Lupus Erythematosus ,Article ,Disease activity ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,Internal medicine ,medicine ,Lupus Nephritis ,Medicine (all) ,In patient ,030212 general & internal medicine ,skin and connective tissue diseases ,030203 arthritis & rheumatology ,business.industry ,Orvostudományok ,General Medicine ,medicine.disease ,Disease control ,3. Good health ,Rituximab ,business ,medicine.drug - Abstract
OBJECTIVES: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy.METHODS: Data on patients with SLE receiving RTX were taken from the International Registry for Biologics in SLE retrospective registry and complemented with data on patients with SLE treated with conventional therapy. For nationwide estimates of RTX use in patients with SLE, investigators were asked to provide data through case report forms (CRFs). Countries for which no data were submitted through CRFs, published literature and/or personal communication were used, and for European countries where no data were available, estimates were made on the assumption of similarities with neighbouring countries.RESULTS: The estimated off-label use of RTX in Europe was 0.5%-1.5% of all patients with SLE. In comparison with patients with SLE on conventional therapy, patients treated with RTX had longer disease duration, higher disease activity and were more often treated with immunosuppressives. The most frequent organ manifestations for which either RTX or conventional therapy was initiated were lupus nephritis followed by musculoskeletal and haematological. The reason for treatment was, besides disease control, corticosteroid-sparing for patients treated with conventional therapy.CONCLUSIONS: RTX use for SLE in Europe is restrictive and appears to be used as a last resort in patients for whom other reasonable options have been exhausted.
- Published
- 2016
- Full Text
- View/download PDF
31. A Wide Spectrum of Ocular Manifestations Signify Patients with Systemic Sclerosis.
- Author
-
Szucs, Gabriella, Szekanecz, Zoltan, Aszalos, Zsuzsa, Gesztelyi, Rudolf, Zsuga, Judit, Szodoray, Peter, and Kemeny-Beke, Adam
- Subjects
- *
OCULAR manifestations of general diseases , *SYSTEMIC scleroderma , *DRY eye syndromes , *CONNECTIVE tissue diseases , *DISEASE duration - Abstract
Objectives: Systemic sclerosis (SSc) is a rare, chronic connective tissue disease involving multiple organ systems, including the eye. We evaluated the detailed clinical ocular manifestations of outpatients with SSc.Methods: Demographics, disease duration and subtype, nailfold capillaroscopy (NFC) patterns and laboratory parameters encompassing the autoantibody profile of 51 SSc patients were evaluated, and a general ocular examination was performed for each participant.Results: Twenty-nine patients (56.86%) had eyelid skin alterations, 26 (50.98%) had retinal abnormalities, 26 (50.98%) had cataracts, 8 (15.69%) had conjunctival changes, 7 (13.73%) had iris abnormalities, 33 (64.71%) suffered from dry eye disease (DED), and 11 (21.57%) suffered from glaucoma. Significant positive correlations were found between NFC data and both tear breakup time and Ocular Surface Disease Index test values.Conclusions: Eyelid skin abnormalities, DED and retinal abnormalities are among the most common SSc-related ocular involvements. Diverse ophthalmic findings are attributed to the heterogeneity of SSc. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Update of EULAR recommendations for the treatment of systemic sclerosis
- Author
-
UMC Utrecht, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Kowal-Bielecka, Otylia, Fransen, Jaap, Avouac, Jerome, Becker, Mike, Kulak, Agnieszka, Allanore, Yannick, Distler, Oliver, Clements, Philip, Cutolo, Maurizio, Czirjak, Laszlo, Damjanov, Nemanja, del Galdo, Francesco, Denton, Christopher P., Distler, Jörg H W, Foeldvari, Ivan, Figelstone, Kim, Frerix, Marc, Furst, Daniel E., Guiducci, Serena, Hunzelmann, Nicolas, Khanna, Dinesh, Matucci-Cerinic, Marco, Herrick, Ariane L., van den Hoogen, Frank, van Laar, Jacob M., Riemekasten, Gabriela, Silver, Richard, Smith, Vanessa, Sulli, Alberto, Tarner, Ingo, Tyndall, Alan, Welling, Joep, Wigley, Frederic, Valentini, Gabriele, Walker, Ulrich A., Zulian, Francesco, Müller-Ladner, Ulf, Daikeler, Thomas, Lanciano, Elisabetta, Becvár, Radim, Tomcik, Michal, Gindzienska-Sieskiewicz, Ewa, Iudici, Michele, Rednic, Simona, Vlachoyiannopoulos, Panayiotis G., Caporali, Roberto, Carreira, Patricia E., Novak, Srdan, Minier, Tünde, Kucharz, Eugene J., Gabrielli, Armando, Moroncini, Gianluca, Airo, Paolo, Hesselstrand, Roger, Martinovic, Duska, Radic, Mislav, Marasovic-Krstulovic, Daniela, Braun-Moscovici, Yolanda, Monaco, Andrea Lo, Morovic-Vergles, Jadranka, Culo, Melanie I., Henes, Jörg, Santamaria, Vera Ortiz, Heitmann, Stefan, Krasowska, Dorota, Michalska-Jakubus, Malgorzata, Seidel, Matthias F., Klinik, Medizinische, Hasler, Paul, Da Silva, José A Pereira, Salvador, Maria J., Stamenkovic, Bojana, Stankovic, Aleksandra, Tikly, Mohammed, Ananieva, Lidia P., Beretta, Lorenzo, Szucs, Gabriella, Szamosi, Szilvia, de la Puente Bujidos, Carlos, Midtvedt, Øyvind, Hoffmann-Vold, Anna Maria, Launay, David, Hachulla, Eric, Riccieri, Valeria, Ionescu, Ruxandra, Opris, Daniela, Mihai, Carina, Herrgott, Ilka, Beyer, Christian, Ingegnoli, Francesca, von Mühlen, Carlos Alberto, Alegre-Sancho, Juan José, Beltran-Catalan, Emma, Aringer, Martin, Fantana, Julia, Leuchten, Nicolai, Tausche, Anne Kathrin, Langhe, Ellen De, Vanthuyne, Marie, Anic, Branimir, Barešic, Marko, Mayer, Miroslav, üprus, Maria, Otsa, Kati, Yavuz, Sule, Granel, Brigitte, Jimenez, Sergio A., Popa, Serghei, Agachi, Svetlana, Zenone, Thierry, Stebbings, Simon, Dockerty, Joanne, Vacca, Alessandra, Schollum, Joanna, Veale, Douglas J., Toloza, Sergio, Xu, Dong, Olas, Jacek, Rosato, Edoardo, Foti, Rosario, Adler, Sabine, Dan, Diana, Wiesik-Szewczyk, Ewa, Olesinska, Marzena, Kayser, Cristiane, Fathi, Nihal, de la Peña Lefebvre, Paloma García, Imbert, Bernard, UMC Utrecht, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, Kowal-Bielecka, Otylia, Fransen, Jaap, Avouac, Jerome, Becker, Mike, Kulak, Agnieszka, Allanore, Yannick, Distler, Oliver, Clements, Philip, Cutolo, Maurizio, Czirjak, Laszlo, Damjanov, Nemanja, del Galdo, Francesco, Denton, Christopher P., Distler, Jörg H W, Foeldvari, Ivan, Figelstone, Kim, Frerix, Marc, Furst, Daniel E., Guiducci, Serena, Hunzelmann, Nicolas, Khanna, Dinesh, Matucci-Cerinic, Marco, Herrick, Ariane L., van den Hoogen, Frank, van Laar, Jacob M., Riemekasten, Gabriela, Silver, Richard, Smith, Vanessa, Sulli, Alberto, Tarner, Ingo, Tyndall, Alan, Welling, Joep, Wigley, Frederic, Valentini, Gabriele, Walker, Ulrich A., Zulian, Francesco, Müller-Ladner, Ulf, Daikeler, Thomas, Lanciano, Elisabetta, Becvár, Radim, Tomcik, Michal, Gindzienska-Sieskiewicz, Ewa, Iudici, Michele, Rednic, Simona, Vlachoyiannopoulos, Panayiotis G., Caporali, Roberto, Carreira, Patricia E., Novak, Srdan, Minier, Tünde, Kucharz, Eugene J., Gabrielli, Armando, Moroncini, Gianluca, Airo, Paolo, Hesselstrand, Roger, Martinovic, Duska, Radic, Mislav, Marasovic-Krstulovic, Daniela, Braun-Moscovici, Yolanda, Monaco, Andrea Lo, Morovic-Vergles, Jadranka, Culo, Melanie I., Henes, Jörg, Santamaria, Vera Ortiz, Heitmann, Stefan, Krasowska, Dorota, Michalska-Jakubus, Malgorzata, Seidel, Matthias F., Klinik, Medizinische, Hasler, Paul, Da Silva, José A Pereira, Salvador, Maria J., Stamenkovic, Bojana, Stankovic, Aleksandra, Tikly, Mohammed, Ananieva, Lidia P., Beretta, Lorenzo, Szucs, Gabriella, Szamosi, Szilvia, de la Puente Bujidos, Carlos, Midtvedt, Øyvind, Hoffmann-Vold, Anna Maria, Launay, David, Hachulla, Eric, Riccieri, Valeria, Ionescu, Ruxandra, Opris, Daniela, Mihai, Carina, Herrgott, Ilka, Beyer, Christian, Ingegnoli, Francesca, von Mühlen, Carlos Alberto, Alegre-Sancho, Juan José, Beltran-Catalan, Emma, Aringer, Martin, Fantana, Julia, Leuchten, Nicolai, Tausche, Anne Kathrin, Langhe, Ellen De, Vanthuyne, Marie, Anic, Branimir, Barešic, Marko, Mayer, Miroslav, üprus, Maria, Otsa, Kati, Yavuz, Sule, Granel, Brigitte, Jimenez, Sergio A., Popa, Serghei, Agachi, Svetlana, Zenone, Thierry, Stebbings, Simon, Dockerty, Joanne, Vacca, Alessandra, Schollum, Joanna, Veale, Douglas J., Toloza, Sergio, Xu, Dong, Olas, Jacek, Rosato, Edoardo, Foti, Rosario, Adler, Sabine, Dan, Diana, Wiesik-Szewczyk, Ewa, Olesinska, Marzena, Kayser, Cristiane, Fathi, Nihal, de la Peña Lefebvre, Paloma García, and Imbert, Bernard
- Published
- 2017
33. Mapping and predicting mortality from systemic sclerosis
- Author
-
Elhai, Muriel, Meune, Christophe, Boubaya, Marouane, Avouac, Jerome, Hachulla, Eric, Balbir-Gurman, Alexandra, Riemekasten, Gabriela, Airo, Paolo, Joven, Beatriz, Vettori, Serena, Cozzi, Franco, Ullman, Susanne, Czirjak, Laszlo, Tikly, Mohammed, Mueller-Ladner, U. L. F., Caramaschi, Paola, Distler, Oliver, Iannone, Florenzo, Ananieva, Lidia P., Hesselstrand, Roger, Becvar, Radim, Gabrielli, Armando, Damjanov, Nemanja, Salvador, Maria J., Riccieri, Valeria, Mihai, Carina, Szucs, Gabriella, Walker, Ulrich A., Hunzelmann, Nicolas, Martinovic, Duska, Smith, Vanessa, Mueller, Carolina de Souza, Montecucco, Carlo Maurizio, Opris, Daniela, Ingegnoli, Francesca, Vlachoyiannopoulos, Panayiotis G., Stamenkovic, Bojana, Rosato, Edoardo, Heitmann, Stefan, Distler, Joerg H. W., Zenone, Thierry, Seidel, Matthias, Vacca, Alessandra, De langhe, Ellen, Novak, Srdan, Cutolo, Maurizio, Mouthon, Luc, Henes, Joerg, Chizzolini, Carlo, von Muhlen, Carlos Alberto, Solanki, Kamal, Rednic, Simona, Stamp, Lisa, Anic, Branimir, Santamaria, Vera Ortiz, De Santis, Maria, Yavuz, Sule, Alberto Sifuentes-Giraldo, Walter, Chatelus, Emmanuel, Stork, Jiri, van Laar, Jacob, Loyo, Esthela, de la Pena Lefebvre, Paloma Garcia, Eyerich, Kilian, Cosentino, Vanesa, Jose Alegre-Sancho, Juan, Kowal-Bielecka, Otylia, Rey, Gregoire, Matucci-Cerinic, Marco, Allanore, Yannick, Elhai, Muriel, Meune, Christophe, Boubaya, Marouane, Avouac, Jerome, Hachulla, Eric, Balbir-Gurman, Alexandra, Riemekasten, Gabriela, Airo, Paolo, Joven, Beatriz, Vettori, Serena, Cozzi, Franco, Ullman, Susanne, Czirjak, Laszlo, Tikly, Mohammed, Mueller-Ladner, U. L. F., Caramaschi, Paola, Distler, Oliver, Iannone, Florenzo, Ananieva, Lidia P., Hesselstrand, Roger, Becvar, Radim, Gabrielli, Armando, Damjanov, Nemanja, Salvador, Maria J., Riccieri, Valeria, Mihai, Carina, Szucs, Gabriella, Walker, Ulrich A., Hunzelmann, Nicolas, Martinovic, Duska, Smith, Vanessa, Mueller, Carolina de Souza, Montecucco, Carlo Maurizio, Opris, Daniela, Ingegnoli, Francesca, Vlachoyiannopoulos, Panayiotis G., Stamenkovic, Bojana, Rosato, Edoardo, Heitmann, Stefan, Distler, Joerg H. W., Zenone, Thierry, Seidel, Matthias, Vacca, Alessandra, De langhe, Ellen, Novak, Srdan, Cutolo, Maurizio, Mouthon, Luc, Henes, Joerg, Chizzolini, Carlo, von Muhlen, Carlos Alberto, Solanki, Kamal, Rednic, Simona, Stamp, Lisa, Anic, Branimir, Santamaria, Vera Ortiz, De Santis, Maria, Yavuz, Sule, Alberto Sifuentes-Giraldo, Walter, Chatelus, Emmanuel, Stork, Jiri, van Laar, Jacob, Loyo, Esthela, de la Pena Lefebvre, Paloma Garcia, Eyerich, Kilian, Cosentino, Vanesa, Jose Alegre-Sancho, Juan, Kowal-Bielecka, Otylia, Rey, Gregoire, Matucci-Cerinic, Marco, and Allanore, Yannick
- Abstract
Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc). Methods Between 2000 and 2011, we examined the death certificates of all French patients with SSc to determine causes of death. Then we examined causes of death and developed a score associated with all-cause mortality from the international European Scleroderma Trials and Research (EUSTAR) database. Candidate prognostic factors were tested by Cox proportional hazards regression model by single variable analysis, followed by a multiple variable model stratified by centres. The bootstrapping technique was used for internal validation. Results We identified 2719 French certificates of deaths related to SSc, mainly from cardiac (31%) and respiratory (18%) causes, and an increase in SSc-specific mortality over time. Over a median follow-up of 2.3 years, 1072 (9.6%) of 11 193 patients from the EUSTAR sample died, from cardiac disease in 27% and respiratory causes in 17%. By multiple variable analysis, a risk score was developed, which accurately predicted the 3-year mortality, with an area under the curve of 0.82. The 3-year survival of patients in the upper quartile was 53%, in contrast with 98% in the first quartile. Conclusion Combining two complementary and detailed databases enabled the collection of an unprecedented 3700 deaths, revealing the major contribution of the cardiopulmonary system to SSc mortality. We also developed a robust score to risk-stratify these patients and estimate their 3-year survival. With the emergence of new therapies, these important observations should help caregivers plan and refine the monitoring and management to prolong these patients' survival.
- Published
- 2017
34. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis
- Author
-
van Steenbergen, Hanna W, Aletaha, Daniel, Beaart-van de Voorde, Liesbeth J J, Brouwer, Elisabeth, Codreanu, Catalin, Combe, Bernard, Fonseca, João E., Hetland, Merete L, Humby, Frances, Kvien, Tore K., Niedermann, Karin, Nuno, Laura, Oliver, Sue, Rantapää-Dahlqvist, Solbritt, Raza, Karim, van Schaardenburg, Dirkjan, Schett, Georg, De Smet, Liesbeth, Szucs, Gabriella, Vencovsky, Jirí, Wiland, Piotr, De Wit, Maarten, Landewé, Robert L, van der Helm-van Mil, Annette H M, van Steenbergen, Hanna W, Aletaha, Daniel, Beaart-van de Voorde, Liesbeth J J, Brouwer, Elisabeth, Codreanu, Catalin, Combe, Bernard, Fonseca, João E., Hetland, Merete L, Humby, Frances, Kvien, Tore K., Niedermann, Karin, Nuno, Laura, Oliver, Sue, Rantapää-Dahlqvist, Solbritt, Raza, Karim, van Schaardenburg, Dirkjan, Schett, Georg, De Smet, Liesbeth, Szucs, Gabriella, Vencovsky, Jirí, Wiland, Piotr, De Wit, Maarten, Landewé, Robert L, and van der Helm-van Mil, Annette H M
- Abstract
BACKGROUND: During the transition to rheumatoid arthritis (RA) many patients pass through a phase characterised by the presence of symptoms without clinically apparent synovitis. These symptoms are not well-characterised. This taskforce aimed to define the clinical characteristics of patients with arthralgia who are considered at risk for RA by experts based on their clinical experience.METHODS: The taskforce consisted of 18 rheumatologists, 1 methodologist, 2 patients, 3 health professionals and 1 research fellow. The process had three phases. In phase I, a list of parameters considered characteristic for clinically suspect arthralgia (CSA) was derived; the most important parameters were selected by a three-phased Delphi approach. In phase II, the experts evaluated 50 existing patients on paper, classified them as CSA/no-CSA and indicated their level of confidence. A provisional set of parameters was derived. This was studied for validation in phase III, where all rheumatologists collected patients with and without CSA from their outpatient clinics.RESULTS: The comprehensive list consisted of 55 parameters, of which 16 were considered most important. A multivariable model based on the data from phase II identified seven relevant parameters: symptom duration <1 year, symptoms of metacarpophalangeal (MCP) joints, morning stiffness duration ≥60 min, most severe symptoms in early morning, first-degree relative with RA, difficulty with making a fist and positive squeeze test of MCP joints. In phase III, the combination of these parameters was accurate in identifying patients with arthralgia who were considered at risk of developing RA (area under the receiver operating characteristic curve 0.92, 95% CI 0.87 to 0.96). Test characteristics for different cut-off points were determined.CONCLUSIONS: A set of clinical characteristics for patients with arthralgia who are at risk of progression to RA was established.
- Published
- 2017
35. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis: results from the International Scleroderma Renal Crisis Survey
- Author
-
Hudson, Marie, Baron, Murray, Tatibouet, Solène, Furst, Daniel E., Khanna, Dinesh, Hummers, Laura, Hachulla, Eric, Medsger, Thomas, Steen, Virginia, Alkassab, Firas, Johnson, Sindhu, Midtvedt, Oyvind, Szucs, Gabriella, Schiopu, Elena, Carreira, Patricia E., Derk, Chris T., Distler, Oliver, Inanc, Murat, Khalidi, Nader, Mahmud, Tafazzul H., Mayes, Maureen D., Mckown, Kevin, Proudman, Susanna, Rudnicka, Lidia, Seigel, Stuart, Stein, Jack, Yavuz, Sule, Arbillaga, Hector, Hazel, Beth, Schulz, Jan, Baker, Milton, Becker, Mike, Cabane, Jean, Chow, Andrew, Christmann, Romy, Clements, Philip, Csuka, Mary Ellen, Hanke, Katharina, Kötter, Ina, Jacobsen, Soren, Kur, Jason, Lally, Edward V., Ligier, Sophie, Mittoo, Shikha, Peschken, Christine, De La Pena Lefebvre, Paloma Garcia, Queyrel, Viviane, Silver, Richard, Simms, Robert, Sondergaard, Klaus, Troyanov, Yves, Turi, Maria C., Varga, John, Vlachoyiannopoulos, Panayiotis G., Voskuyl, Alexandre E., Yeadon, Carol, Westhovens, Rene, VALENTINI, Gabriele, Hudson, Marie, Baron, Murray, Tatibouet, Solène, Furst, Daniel E., Khanna, Dinesh, Hummers, Laura, Hachulla, Eric, Medsger, Thoma, Steen, Virginia, Alkassab, Fira, Johnson, Sindhu, Midtvedt, Oyvind, Szucs, Gabriella, Schiopu, Elena, Carreira, Patricia E., Derk, Chris T., Distler, Oliver, Inanc, Murat, Khalidi, Nader, Mahmud, Tafazzul H., Mayes, Maureen D., Mckown, Kevin, Proudman, Susanna, Rudnicka, Lidia, Seigel, Stuart, Stein, Jack, Valentini, Gabriele, Yavuz, Sule, Arbillaga, Hector, Hazel, Beth, Schulz, Jan, Baker, Milton, Becker, Mike, Cabane, Jean, Chow, Andrew, Christmann, Romy, Clements, Philip, Csuka, Mary Ellen, Hanke, Katharina, Kötter, Ina, Jacobsen, Soren, Kur, Jason, Lally, Edward V., Ligier, Sophie, Mittoo, Shikha, Peschken, Christine, De La Pena Lefebvre, Paloma Garcia, Queyrel, Viviane, Silver, Richard, Simms, Robert, Sondergaard, Klau, Troyanov, Yve, Turi, Maria C., Varga, John, Vlachoyiannopoulos, Panayiotis G., Voskuyl, Alexandre E., Yeadon, Carol, and Westhovens, Rene
- Subjects
Adult ,Male ,medicine.medical_specialty ,Kidney Disease ,medicine.medical_treatment ,Scleroderma Renal Crisis ,Angiotensin-Converting Enzyme Inhibitors ,Scleroderma renal crisi ,Klinikai orvostudományok ,Severity of Illness Index ,Scleroderma ,Follow-Up Studie ,Cohort Studies ,Rheumatology ,ACE inhibitor ,Internal medicine ,Severity of illness ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Dialysis ,Aged ,Scleroderma, Systemic ,business.industry ,Medicine (all) ,Confounding ,Hazard ratio ,Angiotensin-Converting Enzyme Inhibitor ,Orvostudományok ,Middle Aged ,Prospective Studie ,Anesthesiology and Pain Medicine ,Endocrinology ,Kidney Diseases ,Female ,Cohort Studie ,business ,Follow-Up Studies ,Human ,Cohort study ,Proto-oncogene tyrosine-protein kinase Src - Abstract
Objective To determine whether exposure to angiotensin-converting enzyme (ACE) inhibitors prior to the onset of scleroderma renal crisis (SRC) leads to worse outcomes of SRC. Methods Prospective cohort study of incident SRC subjects. The exposure of interest was ACE inhibitors prior to the onset of SRC. The outcomes of interest were death or dialysis during the first year after the onset of SRC. Results A total of 87 subjects with incident SRC were identified and 1-year follow-up data were obtained in 75 (86%) subjects. Overall, 27 (36%) subjects died within the first year and an additional 19 (25%) remained on dialysis 1 year after the onset of SRC. In adjusted analyses, exposure to ACE inhibitors prior to the onset of SRC was associated with an increased risk of death (hazard ratio 2.42, 95% CI 1.02, 5.75, p p = 0.09 after post-hoc adjustment for pre-existing hypertension). Conclusion Overall, the 1-year outcomes of SRC were poor. Prior exposure to ACE inhibitors was associated with an increased risk of death after the onset of SRC, although there was uncertainty around the magnitude of the risk and the possibility of residual confounding could not be ruled out. Further studies will be needed to confirm these findings.
- Published
- 2014
36. Evaluation of commonly used tear sampling methods and their relevance in subsequent biochemical analysis
- Author
-
Rentka, Aniko, primary, Koroskenyi, Krisztina, additional, Harsfalvi, Jolan, additional, Szekanecz, Zoltan, additional, Szucs, Gabriella, additional, Szodoray, Peter, additional, and Kemeny-Beke, Adam, additional
- Published
- 2017
- Full Text
- View/download PDF
37. Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis
- Author
-
Rentka, Aniko, primary, Harsfalvi, Jolan, additional, Szucs, Gabriella, additional, Szekanecz, Zoltan, additional, Szodoray, Peter, additional, Koroskenyi, Krisztina, additional, and Kemeny-Beke, Adam, additional
- Published
- 2015
- Full Text
- View/download PDF
38. Hyperferritinemia is Associated with Serologic Antiphospholipid Syndrome in SLE Patients
- Author
-
Zandman-Goddard, Gisele, primary, Orbach, Hedi, additional, Agmon-Levin, Nancy, additional, Boaz, Mona, additional, Amital, Howard, additional, Szekanecz, Zoltan, additional, Szucs, Gabriella, additional, Rovensky, Josef, additional, Kiss, Emese, additional, Corocher, Nadia, additional, Doria, Andrea, additional, Stojanovich, Ljudmila, additional, Ingegnoli, Francesca, additional, Meroni, Pier Luigi, additional, Rozman, Blaz, additional, Gomez-Arbesu, Jesus, additional, Blank, Miri, additional, and Shoenfeld, Yehuda, additional
- Published
- 2011
- Full Text
- View/download PDF
39. Prolactin and Autoimmunity
- Author
-
Orbach, Hedi, primary, Zandman-Goddard, Gisele, additional, Boaz, Mona, additional, Agmon-Levin, Nancy, additional, Amital, Howard, additional, Szekanecz, Zoltan, additional, Szucs, Gabriella, additional, Rovensky, Josef, additional, Kiss, Emese, additional, Doria, Andrea, additional, Ghirardello, Anna, additional, Gomez-Arbesu, Jesus, additional, Stojanovich, Ljudmila, additional, Ingegnoli, Francesca, additional, Meroni, Pier Luigi, additional, Rozman, Blaz’, additional, Blank, Miri, additional, and Shoenfeld, Yehuda, additional
- Published
- 2011
- Full Text
- View/download PDF
40. Determination of ligand binding capacity of soluble FcγRII and FcγRIII in sera of patients with SLE
- Author
-
Csipo, Istvan, primary, Barath, Sandor, additional, Kiss, Emese, additional, Szucs, Gabriella, additional, Szegedi, Gyula, additional, and Kavai, Maria, additional
- Published
- 2007
- Full Text
- View/download PDF
41. Chemokines in Rheumatic Diseases
- Author
-
Szekanecz, Zoltan, primary, Szucs, Gabriella, additional, Szanto, Sandor, additional, and Koch, Alisa, additional
- Published
- 2006
- Full Text
- View/download PDF
42. Real-life experience with switching TNF-[alpha] inhibitors in ankylosing spondylitis.
- Author
-
Gulyas, Katalin, Bodnar, Nora, Nagy, Zsofia, Szamosi, Szilvia, Horvath, Agnes, Vancsa, Andrea, Vegh, Edit, Szabo, Zoltan, Szucs, Gabriella, Szekanecz, Zoltan, and Szanto, Sandor
- Published
- 2014
- Full Text
- View/download PDF
43. Update of EULAR recommendations for the treatment of systemic sclerosis
- Author
-
Kowal-Bielecka O., Fransen J., Avouac J., Becker M., Kulak A., Allanore Y., Distler O., Clements P., Cutolo M., Czirjak L., Damjanov N., Del Galdo F., Denton C. P., Distler J. H. W., Foeldvari I., Figelstone K., Frerix M., Furst D. E., Guiducci S., Hunzelmann N., Khanna D., Matucci-Cerinic M., Herrick A. L., Van Den Hoogen F., Van Laar J. M., Riemekasten G., Silver R., Smith V., Sulli A., Tarner I., Tyndall A., Welling J., Wigley F., Valentini G., Walker U. A., Zulian F., Muller-Ladner U., Daikeler T., Lanciano E., Becvar R., Tomcik M., Gindzienska-Sieskiewicz E., Cuomo G., Iudici M., Rednic S., Vlachoyiannopoulos P. G., Caporali R., Carreira P. E., Novak S., Minier T., Kucharz E. J., Gabrielli A., Moroncini G., Airo' P., Hesselstrand R., Martinovic D., Radic M., Marasovic-Krstulovic D., Braun-Moscovici Y., Balbir-Gurman A., Lo Monaco A., Caramaschi P., Morovic-Vergles J., Henes J., Ortiz Santamaria V., Heitmann S., Krasowska D., Seidel M. F., Hasler P., Pereira Da Silva J. A., Salvador M. J., Stamenkovic B., Stankovic A., Tikly M., Ananieva L. P., Beretta L., Szucs G., Szamosi S., de la Puente Bujidos C., Midtvedt O., Hoffmann-Vold A. -M., Launay D., Hachulla E., Riccieri V., Ionescu R., Opris D., Mihai C., Herrgott I., Beyer C., Ingegnoli F., von Muhlen C. A., Alegre-Sancho J. J., Beltran-Catalan E., Aringer M., Fantana J., Leuchten N., Tausche A. -K., De Langhe E., Vanthuyne M., Anic B., Baresic M., Mayer M., Uprus M., Otsa K., Yavuz S., Granel B., Azevedo V. F., Muller C., Jimenez S. A., Popa S., Agachi S., Zenone T., Stebbings S., Dockerty J., Vacca A., Schollum J., Veale D. J., Toloza S., Xu D., Olas J., Rosato E., Foti R., Adler S., Dan D., Wiesik-Szewczyk E., Olesinska M., Kayser C., Fathi N., de la Pena Lefebvre P. G., Imbert B., Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., Damjanov, N., Del Galdo, F., Denton, C. P., Distler, J. H. W., Foeldvari, I., Figelstone, K., Frerix, M., Furst, D. E., Guiducci, S., Hunzelmann, N., Khanna, D., Matucci-Cerinic, M., Herrick, A. L., Van Den Hoogen, F., Van Laar, J. M., Riemekasten, G., Silver, R., Smith, V., Sulli, A., Tarner, I., Tyndall, A., Welling, J., Wigley, F., Valentini, G., Walker, U. A., Zulian, F., Muller-Ladner, U., Daikeler, T., Lanciano, E., Becvar, R., Tomcik, M., Gindzienska-Sieskiewicz, E., Cuomo, G., Iudici, M., Rednic, S., Vlachoyiannopoulos, P. G., Caporali, R., Carreira, P. E., Novak, S., Minier, T., Kucharz, E. J., Gabrielli, A., Moroncini, G., Airo', P., Hesselstrand, R., Martinovic, D., Radic, M., Marasovic-Krstulovic, D., Braun-Moscovici, Y., Balbir-Gurman, A., Lo Monaco, A., Caramaschi, P., Morovic-Vergles, J., Henes, J., Ortiz Santamaria, V., Heitmann, S., Krasowska, D., Seidel, M. F., Hasler, P., Pereira Da Silva, J. A., Salvador, M. J., Stamenkovic, B., Stankovic, A., Tikly, M., Ananieva, L. P., Beretta, L., Szucs, G., Szamosi, S., de la Puente Bujidos, C., Midtvedt, O., Hoffmann-Vold, A. -M., Launay, D., Hachulla, E., Riccieri, V., Ionescu, R., Opris, D., Mihai, C., Herrgott, I., Beyer, C., Ingegnoli, F., von Muhlen, C. A., Alegre-Sancho, J. J., Beltran-Catalan, E., Aringer, M., Fantana, J., Leuchten, N., Tausche, A. -K., De Langhe, E., Vanthuyne, M., Anic, B., Baresic, M., Mayer, M., Uprus, M., Otsa, K., Yavuz, S., Granel, B., Azevedo, V. F., Muller, C., Jimenez, S. A., Popa, S., Agachi, S., Zenone, T., Stebbings, S., Dockerty, J., Vacca, A., Schollum, J., Veale, D. J., Toloza, S., Xu, D., Olas, J., Rosato, E., Foti, R., Adler, S., Dan, D., Wiesik-Szewczyk, E., Olesinska, M., Kayser, C., Fathi, N., de la Pena Lefebvre, P. G., Imbert, B., UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (MGD) Service de rhumatologie, Kowal Bielecka, Otylia, Fransen, Jaap, Avouac, Jerome, Becker, Mike, Kulak, Agnieszka, Allanore, Yannick, Distler, Oliver, Clements, Philip, Cutolo, Maurizio, Czirjak, Laszlo, Damjanov, Nemanja, del Galdo, Francesco, Denton, Christopher P., Distler, Jörg H. W., Foeldvari, Ivan, Figelstone, Kim, Frerix, Marc, Furst, Daniel E., Guiducci, Serena, Hunzelmann, Nicola, Khanna, Dinesh, Matucci Cerinic, Marco, Herrick, Ariane L., van den Hoogen, Frank, van Laar, Jacob M., Riemekasten, Gabriela, Silver, Richard, Smith, Vanessa, Sulli, Alberto, Tarner, Ingo, Tyndall, Alan, Welling, Joep, Wigley, Frederic, Valentini, Gabriele, Walker, Ulrich A., Zulian, Francesco, Müller Ladner, Ulf, Daikeler, Thoma, Lanciano, Elisabetta, Becvã¡r, Radim, Tomcik, Michal, Gindzienska Sieskiewicz, Ewa, Iudici, Michele, Rednic, Simona, Vlachoyiannopoulos, Panayiotis G., Caporali, Roberto, Carreira, Patricia E., Novak, Srdan, Minier, Tã¼nde, Kucharz, Eugene J., Gabrielli, Armando, Moroncini, Gianluca, Airo, Paolo, Hesselstrand, Roger, Martinovic, Duska, Radic, Mislav, Marasovic Krstulovic, Daniela, Braun Moscovici, Yolanda, Monaco, Andrea Lo, Morovic Vergles, Jadranka, Culo, Melanie I., Henes, Jã¶rg, Santamaria, Vera Ortiz, Heitmann, Stefan, Krasowska, Dorota, Michalska Jakubus, Malgorzata, Seidel, Matthias F., Klinik III, Medizinische, Hasler, Paul, Da Silva, José A. Pereira, Salvador, Maria J., Stamenkovic, Bojana, Stankovic, Aleksandra, Tikly, Mohammed, Ananieva, Lidia P., Beretta, Lorenzo, Szucs, Gabriella, Szamosi, Szilvia, de la Puente Bujidos, Carlo, Midtvedt, Øyvind, Hoffmann Vold, Anna Maria, Launay, David, Hachulla, Eric, Riccieri, Valeria, Ionescu, Ruxandra, Opris, Daniela, Mihai, Carina, Herrgott, Ilka, Beyer, Christian, Ingegnoli, Francesca, von Mühlen, Carlos Alberto, Alegre Sancho, Juan José, Beltran Catalan, Emma, Aringer, Martin, Fantana, Julia, Leuchten, Nicolai, Tausche, Anne Kathrin, Langhe, Ellen De, Vanthuyne, Marie, Anic, Branimir, Bareå¡ic, Marko, Mayer, Miroslav, Ãœprus, Maria, Otsa, Kati, Yavuz, Sule, Granel, Brigitte, Jimenez, Sergio A., Popa, Serghei, Agachi, Svetlana, Zenone, Thierry, Stebbings, Simon, Dockerty, Joanne, Vacca, Alessandra, Schollum, Joanna, Veale, Douglas J., Toloza, Sergio, Xu, Dong, Olas, Jacek, Rosato, Edoardo, Foti, Rosario, Adler, Sabine, Dan, Diana, Wiesik Szewczyk, Ewa, Olesinska, Marzena, Kayser, Cristiane, Fathi, Nihal, de la Peña Lefebvre, Paloma GarcÃa, Imbert, Bernard, and Cuomo, Giovanna
- Subjects
Endothelin Receptor Antagonists ,Lung Diseases ,Kidney Disease ,Delphi Technique ,Gastrointestinal Diseases ,systemic sclerosis ,Scleroderma Renal Crisis ,Placebo-controlled study ,Angiotensin-Converting Enzyme Inhibitors ,Lung Disease ,Scleroderma ,0302 clinical medicine ,Glucocorticoid ,Phosphodiesterase 5 Inhibitor ,Immunology and Allergy ,skin and connective tissue diseases ,BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina ,integumentary system ,treatment ,genetics and molecular biology (all) ,Hematopoietic Stem Cell Transplantation ,cyclophosphamide ,methotrexate ,Pulmonary ,Orvostudományok ,Serotonin Uptake Inhibitor ,3. Good health ,Europe ,Systematic review ,Hypertension ,Serotonin Uptake Inhibitors ,Cyclophosphamide ,Methotrexate ,Systemic Sclerosis ,Treatment ,Fingers ,Fluoxetine ,Glucocorticoids ,Humans ,Hypertension, Pulmonary ,Kidney Diseases ,Phosphodiesterase 5 Inhibitors ,Prostaglandins I ,Pyrazoles ,Pyrimidines ,Raynaud Disease ,Rheumatology ,Scleroderma, Systemic ,Ulcer ,Immunology ,Biochemistry, Genetics and Molecular Biology (all) ,030211 gastroenterology & hepatology ,Endothelin Receptor Antagonist ,Selective Serotonin Reuptake Inhibitors ,medicine.drug ,Human ,medicine.medical_specialty ,Gastrointestinal Disease ,Klinikai orvostudományok ,Riociguat ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,medicine ,Finger ,biochemistry ,Intensive care medicine ,BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine ,Systemic Sclerosi ,030203 arthritis & rheumatology ,business.industry ,Systemic ,Angiotensin-Converting Enzyme Inhibitor ,medicine.disease ,Transplantation ,Clinical research ,Pyrimidine ,immunology and allergy ,rheumatology ,immunology ,Pyrazole ,Physical therapy ,business ,Rheumatism - Abstract
The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. Update of the previous treatment recommendations was performed according to EULAR standard operating procedures. The task force consisted of 32 SSc clinical experts from Europe and the USA, 2 patients nominated by the pan-European patient association for SSc (Federation of European Scleroderma Associations (FESCA)), a clinical epidemiologist and 2 research fellows. All centres from the EULAR Scleroderma Trials and Research group were invited to submit and select clinical questions concerning SSc treatment using a Delphi approach. Accordingly, 46 clinical questions addressing 26 different interventions were selected for systematic literature review. The new recommendations were based on the available evidence and developed in a consensus meeting with clinical experts and patients. The procedure resulted in 16 recommendations being developed (instead of 14 in 2009) that address treatment of several SSc-related organ complications: Raynaud's phenomenon (RP), digital ulcers (DUs), pulmonary arterial hypertension (PAH), skin and lung disease, scleroderma renal crisis and gastrointestinal involvement. Compared with the 2009 recommendations, the 2016 recommendations include phosphodiesterase type 5 (PDE-5) inhibitors for the treatment of SSc-related RP and DUs, riociguat, new aspects for endothelin receptor antagonists, prostacyclin analogues and PDE-5 inhibitors for SSc-related PAH. New recommendations regarding the use of fluoxetine for SSc-related RP and haematopoietic stem cell transplantation for selected patients with rapidly progressive SSc were also added. In addition, several comments regarding other treatments addressed in clinical questions and suggestions for the SSc research agenda were formulated. These updated data-derived and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc.
- Published
- 2017
- Full Text
- View/download PDF
44. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
- Author
-
Váncsa A, Szabó Z, Szamosi S, Bodnár N, Végh E, Gergely L, Szucs G, Szántó S, and Szekanecz Z
- Subjects
- Adult, Aged, Arthritis, Rheumatoid blood, Arthritis, Rheumatoid immunology, Autoantibodies blood, B-Lymphocytes pathology, Cell Count, Cell Separation, Female, Flow Cytometry, Health Status, Humans, Leukocyte Count, Male, Middle Aged, Prospective Studies, Reproducibility of Results, Rituximab, Severity of Illness Index, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Murine-Derived adverse effects, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid drug therapy, B-Lymphocytes drug effects, Lymphocyte Depletion
- Abstract
Objective: To assess the efficacy and safety of longterm rituximab (RTX) therapy for rheumatoid arthritis (RA) and study correlations among B cell depletion, clinical response, and autoantibody production., Methods: Seventy-seven patients with moderate or high RA activity received RTX and were re-treated every 6 months regardless of clinical response. All patients received at least 5 cycles. We assessed 28-joint Disease Activity Score (DAS28), IgM rheumatoid factor (RF), and anticitrullinated protein antibody (ACPA) levels at baseline, after 15 days, and then every 6 months for 24 months. Absolute CD19+ B lymphocyte counts were determined in 50 patients using high-sensitivity flow cytometry (hsFACS) by reading 100,000 events., Results: After 6, 12, 18, and 24 months, 51.6%, 51.9%, 73.3%, and 83.8% of patients, respectively, showed good European League Against Rheumatism responses. Significant and sustained decreases in IgM RF and ACPA levels were observed as early as 6 months and 12 months, respectively. The baseline mean absolute B cell number was 0.234 g/l. B cell numbers diminished significantly after the very first infusion by Day 15 (0.104 g/l; p = 0.007); they further decreased until 24 months (0.0013 g/l; p < 0.001). One RTX infusion resulted in incomplete depletion in 76.7% of patients. Upon RTX treatment, changes in CD19+ B cell numbers positively correlated with changes in DAS28 (r = 0.963, p = 0.008) and IgM RF (r = 0.859, p = 0.028), but not with changes in ACPA production (r = 0.726, p = 0.102). The correlations between B cell numbers and DAS28 were observed in both ACPA-seropositive (r = 0.999, p < 0.0001) and ACPA-negative patient subpopulations (r = 0.962, p = 0.009). The correlation between CD19+ cell numbers and IgM RF was observed only in the ACPA-positive population (r = 0.944, p = 0.005) but not in seronegative patients (r = 0.398, p = 0.435). No safety issues arose., Conclusion: In RA, clinical response to RTX is associated with the extent of B cell depletion and with autoantibody production. Changes in CD19+ B cell numbers correlate with those in disease activity and, in seropositive patients, also with IgM RF, but not with ACPA production. We found that hsFACS may be a useful method to more accurately assess incomplete B cell depletion.
- Published
- 2013
- Full Text
- View/download PDF
45. Malignancy or inflammation? A case report of a young man with fever of unknown origin.
- Author
-
Harangi M, Kovács T, Rákóczi É, Rejto L, Mikó L, Tóth L, Szucs G, Galuska L, and Paragh G
- Subjects
- Adult, Anti-Infective Agents therapeutic use, Chronic Disease, Ciprofloxacin therapeutic use, Fever of Unknown Origin drug therapy, Humans, Male, Fever of Unknown Origin etiology, Osteomyelitis complications, Osteomyelitis diagnosis, Osteomyelitis physiopathology
- Abstract
A case of a young man with fever of unknown origin is presented. This diagnosis can be frustrating for both patients and physicians because the diagnostic workup often involves numerous noninvasive and invasive procedures that sometimes fail to explain the fever. In the presented case some of the imaging diagnostic findings suggested malignant hematological disorder. However, histopathological and microbiological investigation proved vertebral osteomyelitis caused by Staphylococcus haemolyticus. Diagnosis was established by positron emission tomography, magnetic resonance imaging, and culture and histopathological analysis of a spinal biopsy. 3 months of antibiotic therapy was curative. Biopsy and microbiological investigation may be necessary in patients with fever, back pain and evidence of a spinal lesion on imaging, even if neoplastic disease is suspected.
- Published
- 2011
- Full Text
- View/download PDF
46. Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis.
- Author
-
Kerekes G, Soltész P, Szucs G, Szamosi S, Dér H, Szabó Z, Csáthy L, Váncsa A, Szodoray P, Szegedi G, and Szekanecz Z
- Subjects
- Adalimumab, Adult, Aged, Antibodies, Monoclonal, Humanized, Atherosclerosis physiopathology, Brachial Artery diagnostic imaging, Brachial Artery physiopathology, Carotid Artery, Common diagnostic imaging, Carotid Artery, Common physiopathology, Elasticity, Endothelium, Vascular drug effects, Female, Humans, Male, Middle Aged, Ultrasonography, Vascular Diseases etiology, von Willebrand Factor analysis, Antibodies, Monoclonal therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid complications, Atherosclerosis prevention & control, Vascular Diseases prevention & control, Vasodilation drug effects
- Abstract
Background: Increased cardiovascular morbidity has become a leading cause of mortality in rheumatoid arthritis (RA). Tumor necrosis factor-alpha (TNFa) inhibitors may influence flow-mediated vasodilation (FMD) of the brachial artery, common carotid intima-media thickness (ccIMT) and arterial stiffness indicated by pulse-wave velocity (PWV) in RA., Objectives: To assess the effects of adalimumab treatment on FMD, ccIMT and PWV in early RA., Methods: Eight RA patients with a disease duration < or =1 year received 40 mg adalimumab subcutaneously every 2 weeks. Ultrasound was used to assess brachial FMD and ccIMT. PWV was determined by arteriograph. These parameters were correlated with C-reactive protein, vonWillebrand factor (vWF), immunoglobulin M (IgM)-rheumatoid factor (RF), anti-CCP levels and 28-joint disease activity score (DAS28)., Results: Adalimumab therapy successfully ameliorated arthritis as it decreased CRP levels (P = 0.04) and DAS28 (P < 0.0001). Endothelial function (FMD) improved in comparison to baseline (P < 0.05). ccIMT decreased after 24 weeks, indicating a mean 11.9% significant improvement (P = 0.002). Adalimumab relieved arterial stiffness (PWV) after 24 weeks. Although plasma vWF levels decreased only non-significantly after 12 weeks of treatment, an inverse correlation was found between FMD and vWF (R = -0.643, P = 0.007). FMD also inversely correlated with CRP (R = -0.596, P= 0.015). CRP and vWF also correlated with each other (R = 0.598, P = 0.014). PWV and ccIMT showed a positive correlation (R = 0.735, P = 0.038)., Conclusions: Treatment with adalimumab exerted favorable effects on disease activity and endothelial dysfunction. It also ameliorated carotid atherosclerosis and arterial stiffness in patients with early RA. Early adalimumab therapy may have an important role in the prevention and management of vascular comorbidity in RA.
- Published
- 2011
47. Plasma homocysteine levels, the prevalence of methylenetetrahydrofolate reductase gene C677T polymorphism and macrovascular disorders in systemic sclerosis: risk factors for accelerated macrovascular damage?
- Author
-
Szamosi S, Csiki Z, Szomják E, Szolnoki E, Szoke G, Szekanecz Z, Szegedi G, Shoenfeld Y, and Szucs G
- Subjects
- Female, Genetic Predisposition to Disease, Homocysteine blood, Humans, Hypertrophy, Right Ventricular physiopathology, Male, Methylenetetrahydrofolate Reductase (NADPH2) immunology, Middle Aged, Pulmonary Fibrosis physiopathology, Risk Factors, Scleroderma, Systemic blood, Scleroderma, Systemic immunology, Scleroderma, Systemic pathology, Scleroderma, Systemic physiopathology, Thromboembolism physiopathology, Time Factors, Homocysteine immunology, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Polymorphism, Single Nucleotide, Scleroderma, Systemic genetics
- Abstract
The purpose of this study was to investigate plasma homocysteine (Hcy) levels in patients with systemic sclerosis (SSc) and to study the association between plasma Hcy, C677T polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR), and the clinical manifestations in SSc. Associations of Hcy level, C677T MTHFR polymorphism, and macrovascular diseases were investigated in 152 patients with SSc and 58 controls. No significant differences in Hcy levels and MTHFR genotypes were found in SSc patients compared to controls or in SSc patients with limited cutaneous compared to diffuse disease. Significantly higher Hcy concentration was observed in patients with macroangiopathy/thromboembolic events compared to patients without such clinical manifestations (p < 0.05). There was significant correlation between age and macrovascular disorders, between Hcy level and the disease duration (r = 0.164; p < 0.05). Seventy-one percent of patients with macrovascular disorders had MTHFR polymorphism. In addition, 45% of patients with hyperhomocysteinemia had pulmonary hypertension. The presence of MTHFR C677T mutation influences the incidence of macrovascular abnormalities in SSc patients. Elevated Hcy levels may be associated with disease duration and the evolution of macrovascular disorders and pulmonary hypertension in SSc.
- Published
- 2009
- Full Text
- View/download PDF
48. Incidence of lymphoma in systemic sclerosis: a retrospective analysis of 218 Hungarian patients with systemic sclerosis.
- Author
-
Szekanecz E, Szamosi S, Gergely L, Keszthelyi P, Szekanecz Z, and Szucs G
- Subjects
- Aged, Female, Humans, Hungary epidemiology, Lymphoma, B-Cell epidemiology, Middle Aged, Prevalence, Retrospective Studies, Scleroderma, Systemic, Lymphoma, B-Cell complications
- Abstract
Recent results suggest that B cells may have multiple pathogenic roles in systemic sclerosis (SSc) and there may be increased incidence of B cell lymphomas in SSc. Here, we assessed the prevalence of lymphomas in a large SSc cohort. We analyzed data of 218 Hungarian patients undergoing follow-ups in our institutions between 1995 and 2007. During this follow-up period, there were three SSc patients, who eventually developed B cell lymphoma. The first case is a woman with diffuse cutaneous form of SSc (dcSSc) including pulmonary, cardiac, gastrointestinal, and renal manifestations and anti-topoisomerase I antibody positivity. B cell chronic lymphocytic leukemia (B-CLL) with Zap70 expression (Rai I stage) developed 2 years after the onset of SSc. The second case is a woman with dcSSc presenting with pulmonary, cardiac, and gastroesophageal manifestations. Twenty-one months after disease onset, a chronic small lymphocytic B cell non-Hodgkin's lymphoma was diagnosed from retroperitoneal lymph nodes. Our third case is a woman with dcSSc and no internal organ manifestations. She also developed Zap70-positive B-CLL, stage Rai I 9 months after the onset of SSc. Thus, there were three cases of B cell lymphoma among our 218 SSc patients (1.38%). The association of scleroderma and non-Hodgkin's lymphoma may be a rather uncommon feature; however, the incidence of lymphoma among Hungarian SSc patients may be 1.9-2.5 times higher than that in the general population. In our three patients, B cell lymphoma developed within 2 years after the onset of SSc. Altered B cell function implicated in the pathogenesis of SSc may lead to the development of lymphoid malignancies.
- Published
- 2008
- Full Text
- View/download PDF
49. Cutaneous vasculitis as an initiating paraneoplastic symptom in Hodgkin lymphoma.
- Author
-
Simon Z, Tarr T, Tóth L, Szucs G, and Illés A
- Subjects
- Adult, Epstein-Barr Virus Infections complications, Humans, Male, Hodgkin Disease complications, Paraneoplastic Syndromes etiology, Skin Diseases, Vascular etiology, Vasculitis etiology
- Abstract
Skin vasculitis may be associated with infections and autoimmune diseases. Furthermore, vasculitis may appear as a paraneoplastic symptom. A 19-year-old male patient was examined with swollen joints and papules presented on lower extremitis. Laboratory results showed high erythrocyte sedimentation ratio, positive C reactive protein, increased number of leukocytes and high circulating immune complex level. Histopatology of skin biopsy specimen proved vasculitis. ANCA was not present. No other changes could be observed besides skin involvement. Symptoms disappeared on 0.5-mg/bwkg methylprednisolon therapy. Few weeks later, enlarged cervical lymph nodes developed besides fever and weight loss. Biopsy indicated the presence of mixed cell type Hodgkin lymphoma. Appropriate examinations revealed clinical stage III/B with favorable prognosis (IPS=2). After eight cycles of ABVD therapy complete remission was achieved as confirmed by FDG-PET. As a consequence of the treatment of Hodgkin lymphoma, vasculitis also disappeared. The present case report calls to attention the importance of careful examinations to exclude other diseases, especially malignancies that may remain at the background of cutaneous vasculitis. Treatment of the primary disease also results in the improvement of secondary skin vasculitis.
- Published
- 2008
- Full Text
- View/download PDF
50. Determination of ligand binding capacity of soluble Fc gamma RII and Fc gamma RIII in sera of patients with SLE.
- Author
-
Csipo I, Barath S, Kiss E, Szucs G, Szegedi G, and Kavai M
- Subjects
- Humans, Ligands, Lupus Erythematosus, Systemic blood, Protein Binding immunology, Solubility, Lupus Erythematosus, Systemic immunology, Receptors, IgG blood
- Abstract
Background: Soluble, human low affinity Fcgamma receptors, such as sFcgammaRII and sFcgammaRIII, are known to play a pathologic role in different diseases. Sandwich ELISAs had previously been applied for the specific detection and determination of these soluble receptors. In these ELISAs, commercial monoclonal antibodies (Ab) were used as capture antibodies with monoclonal or polyclonal antibodies serving as detector Abs. Increased levels of cell-free FcgammaRIII have been detected in patients with lupus but the functions and levels of sFcgammaRII have not been fully characterized yet., Objectives: The aim of this work was to determine the ligand binding capacities and levels of soluble FcgammaRII and FcgammaRIII in sera of patients with systemic lupus erythematosus (SLE). Moreover, correlation between the levels of sFcgammaRII and sFcgammaRIII and the clinical activity of the disease were investigated., Methods: Sera of 47 patients with SLE, and 51 healthy subjects were analyzed. In the newly developed indirect sandwich ELISAs commercial monoclonal anti-FcgammaRs are used as capture antibodies, and the ligand of FcgammaRII and FcgammaRIII, an artificial immune complex (IC), serves as a detection component replacing the second antibodies used in previous methods., Results: The ligand binding capacity of both soluble FcgammaRII and sFcgammaRIII were elevated in the sera of SLE patients compared to control samples. This increase was significant in patients with the active disease (n = 30; p < 0.01). It was also revealed that a substantial part of the soluble Fcgamma receptors in these patients was bound in vivo to circulating IC., Conclusion: These newly developed ELISAs are probably more phisiologically relevant than other previous assays because they detect the circulating receptors on the basis their in vitro ligan binding capacities. Therefore this method can separately measure the levels of the soluble, free FcgammaRs and those bound circulating IC in vivo.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.